<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004275.pub3" GROUP_ID="UPPERGI" ID="567202072221150874" MERGED_FROM="" MODIFIED="2011-01-03 20:47:09 +0100" MODIFIED_BY="Karin Dearness" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.4&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Jan's amendments July 2004&lt;/p&gt;&lt;p&gt;Old title: Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough&lt;/p&gt;" NOTES_MODIFIED="2009-08-10 15:29:36 +0100" NOTES_MODIFIED_BY="Cathy Bennett" REVIEW_NO="1" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2011-01-03 20:47:09 +0100" MODIFIED_BY="Karin Dearness">
<TITLE>Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough</TITLE>
<CONTACT MODIFIED="2011-01-03 20:47:09 +0100" MODIFIED_BY="Karin Dearness"><PERSON ID="1DA7B8D682E26AA2004A583D1186241F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Yiping</FIRST_NAME><LAST_NAME>Wang</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>wyiping2006@yahoo.com.cn</EMAIL_1><EMAIL_2>wyiping2002@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Digestive Disease</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8554 4437</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-01-03 20:47:09 +0100" MODIFIED_BY="Karin Dearness"><PERSON ID="1DA7B8D682E26AA2004A583D1186241F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Yiping</FIRST_NAME><LAST_NAME>Wang</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>wyiping2006@yahoo.com.cn</EMAIL_1><EMAIL_2>wyiping2002@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Department of Digestive Disease</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8554 4437</PHONE_1></ADDRESS></PERSON><PERSON ID="16701" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Tao</FIRST_NAME><LAST_NAME>Pan</LAST_NAME><EMAIL_1>cnsccdpt@sina.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Gastroenterology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8558 5919</PHONE_1><PHONE_2>+86 28 8542 2385</PHONE_2></ADDRESS></PERSON><PERSON ID="16717" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Qiong</FIRST_NAME><LAST_NAME>Wang</LAST_NAME><EMAIL_1>joanwqcn@sohu.com</EMAIL_1><EMAIL_2>joanwqcn@yahoo.com.cn</EMAIL_2><ADDRESS><DEPARTMENT>Department of Digestive Disease</DEPARTMENT><ORGANISATION>The Third People's Hospital</ORGANISATION><CITY>Chengdu</CITY><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+028 8765 1529</PHONE_1><PHONE_2>+8613709030375</PHONE_2></ADDRESS></PERSON><PERSON ID="3B70A40782E26AA200E15497C1EB33AF" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Zhen</FIRST_NAME><LAST_NAME>Guo</LAST_NAME><EMAIL_1>joan_nick@163.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Digestive Disease</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 2389</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-01-03 20:47:09 +0100" MODIFIED_BY="Karin Dearness">
<UP_TO_DATE>
<DATE DAY="1" MONTH="6" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="29" MONTH="8" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="7" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2011-01-03 20:47:09 +0100" MODIFIED_BY="Karin Dearness"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-01-03 20:47:09 +0100" MODIFIED_BY="Karin Dearness"><DATE DAY="3" MONTH="1" YEAR="2011"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2011-01-03 20:47:09 +0100" MODIFIED_BY="Karin Dearness"><WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-01-03 20:47:09 +0100" MODIFIED_BY="Karin Dearness">
<DATE DAY="1" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>Updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-09 10:54:38 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-09 10:54:42 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="21" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>Minor update: 8/21/06</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-02-09 10:54:47 +0000" MODIFIED_BY="Cathy Bennett">
<DATE DAY="7" MONTH="1" YEAR="2003"/>
<DESCRIPTION>
<P>New studies found and included or excluded: 7/1/03</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Chinese Cochrane Centre, Chinese Centre of Evidence-based Medicine, West China Hospital of Sichuan University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>China Medical Board of New York (Grant number: 98-680)</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-10 15:29:36 +0100" MODIFIED_BY="Cathy Bennett">
<SUMMARY MODIFIED="2009-08-04 11:16:19 +0100" MODIFIED_BY="Cathy Bennett">
<TITLE MODIFIED="2008-11-05 12:44:03 +0000" MODIFIED_BY="Cathy Bennett">Additional bedtime medication for the control of night-time acid reflux from the stomach.</TITLE>
<SUMMARY_BODY MODIFIED="2009-08-04 11:16:19 +0100" MODIFIED_BY="Cathy Bennett">
<P>The inhibition of gastric acid secretion is an accepted treatment for diseases related to reflux of acid from the stomach. Some types of antacids, known as proton pump inhibitors (PPI), are considered to be the most effective medical treatment for people patients with acid-related diseases such as peptic ulcer, gastro-oesophageal reflux disease (GERD) and Zollinger-Ellison syndrome, but they may not reduce gastric acid secretion sufficiently to prevent night-time acid reflux symptoms. H2-receptor antagonists (H2RAs) have also been used for the treatment of acid-related diseases for more than a decade and might help to control night-time acid reflux, if taken at bedtime along with a high dose of PPI. The results show that additional bedtime H2RAs can decrease the night-time gastric acid breakthrough, but we believe that additional bedtime H2RAs to PPI should only be used as treatment an intervention in clinical trials until further evidence has been found.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-04 11:28:50 +0100" MODIFIED_BY="Cathy Bennett">
<ABS_BACKGROUND MODIFIED="2009-08-04 11:28:33 +0100" MODIFIED_BY="Cathy Bennett">
<P>Nocturnal gastric acid breakthrough (NAB) is defined as intragastric pH&lt;4 for more than one continuous hour overnight. Adding H<SUB>2</SUB>-receptor antagonists (H2RAs) at bedtime to high-dose proton pump inhibitors is likely to enhance nocturnal gastric pH control and decrease nocturnal gastric acid breakthrough.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-08-04 11:28:30 +0100" MODIFIED_BY="Cathy Bennett">
<P>To assess the effectiveness of additional bedtime H2-receptor antagonists in suppressing nocturnal gastric acid breakthrough and the incidence of adverse effects.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-07-22 14:18:49 +0100" MODIFIED_BY="Cathy Bennett">
<P>We identified eligible trials by searching The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2008), MEDLINE (1966-August 2008), EMBASE (1980-August 2008) and CINAHL (1982-August 2008). We re-ran the search on CENTRAL (The Cochrane Library Issue 4, 2008), and in MEDLINE, EMBASE and CINAHL in June 2004, July 2005, August 2006 and August 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-08-04 11:16:05 +0100" MODIFIED_BY="Cathy Bennett">
<P>All randomized controlled trials evaluating H2-receptor antagonists for the control of nocturnal gastric acid breakthrough were eligible for inclusion.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-07-22 10:51:54 +0100" MODIFIED_BY="Cathy Bennett">
<P>Two reviewers have independently selected the trials to be included in the review according to the pre-stated eligibility criteria. Disagreements were resolved by a third reviewer. If the data could not be pooled for meta-analysis, a narrative description was provided.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-04 11:28:50 +0100" MODIFIED_BY="Cathy Bennett">
<P>8 small randomized controlled trials were included for meta-analysis. The results show that additional bedtime H2RAs can decrease the prevalence rate of nocturnal gastric acid breakthrough. The results of the analyses for secondary outcomes show that additional bedtime H2RAs can decrease the percentage of time during which pH is less than 4.0 inside the stomach and promote median intragastric pH.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-08-04 11:15:28 +0100" MODIFIED_BY="Cathy Bennett">
<P>We can conclude no implications for practice at this stage. Appropriately designed large-scale randomized controlled trials with long-term follow-up are needed to determine the effects of additional bedtime H2RAs in suppressing nocturnal gastric acid breakthrough.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-08-10 15:29:36 +0100" MODIFIED_BY="Cathy Bennett">
<BACKGROUND MODIFIED="2009-08-04 13:26:31 +0100" MODIFIED_BY="Cathy Bennett" NOTES="&lt;p&gt;I have changed H2 (subscript) to H2 throughout the review as this is not H2 the chemical symbol but histamine-2 receptors.&lt;/p&gt;" NOTES_MODIFIED="2009-08-04 13:26:31 +0100" NOTES_MODIFIED_BY="Cathy Bennett">
<CONDITION MODIFIED="2009-08-04 13:26:31 +0100" MODIFIED_BY="Cathy Bennett">
<P>The inhibition of gastric acid secretion is the cornerstone of the treatment of acid-related diseases. Proton pump inhibitors (PPI), which inhibit the function of the proton pump responsible for the terminal step in gastric acid secretion, are considered to be the most effective medical treatment for the management of patients with acid-related diseases such as peptic ulcer, gastro-oesophageal reflux disease (GERD) and Zollinger-Ellison syndrome (<LINK REF="REF-Bate-1990" TYPE="REFERENCE">Bate 1990</LINK>). However, recent studies have shown that proton pump inhibitors given twice daily, often do not suppress gastric acid secretion sufficiently overnight to prevent recovery of gastric acidity to potentially harmful pH levels(as detected by ambulatory pH monitoring) (<LINK REF="REF-Peghini-1998a" TYPE="REFERENCE">Peghini 1998a</LINK>). This event, known as nocturnal gastric acid breakthrough (NAB), is arbitrarily defined as intragastric pH&lt;4 for more than one continuous hour overnight, and occurs in about 70% of both patients with gastro-oesophageal reflux and normal volunteers (<LINK REF="REF-Peghini-1998a" TYPE="REFERENCE">Peghini 1998a</LINK>). Oesophageal acid exposure occurs in 30-50% of patients during the nocturnal gastric acid breakthrough period (<LINK REF="REF-Katz-1998" TYPE="REFERENCE">Katz 1998</LINK>). This continued nocturnal reflux may be sufficient to produce nocturnal symptoms and mucosal injury in patients with severe erosive oesophagitis, Barrett's oesophagus and extra-oesophageal manifestations of GERD (<LINK REF="REF-Katz-1998" TYPE="REFERENCE">Katz 1998</LINK>). This nocturnal acid breakthrough and accompanying gastro-oesophageal reflux may explain why some GERD patients fail to respond to proton pump inhibitor twice-daily treatment.</P>
<P>In an ex vivo Barrett's oesophagus culture model, some researchers found that short pulses of acid exposure increase proliferation. This suggests that acid-suppressive therapy needs to be powerful enough to completely eliminate any acid pulses and effectively inhibit any cell proliferation. Accomplishing this would allow for a more differentiated state in Barrett's oesophagus epithelia (<LINK REF="REF-Fitzgerald-1996" TYPE="REFERENCE">Fitzgerald 1996</LINK>). In <I>in vivo</I> studies, researchers also proved that effective intra-oesophageal acid suppression not only favours differentiation and decreases proliferation, but also induces partial regression of Barrett's oesophagus (<LINK REF="REF-Ouatu_x002d_Lascar-1999" TYPE="REFERENCE">Ouatu-Lascar 1999</LINK>; <LINK REF="REF-Peters-1999" TYPE="REFERENCE">Peters 1999</LINK>). These patients, who require strict control of gastric acid secretion, demonstrate the clinical rationale for reducing or abolishing NAB.</P>
<P>The mechanism of NAB is not clear, but the factors listed below may be relevant:</P>
<OL>
<LI>Proton pump inhibitors inhibit only active pumps. A dose of PPI given at bedtime was not accompanied by a meal or other stimulus for acid secretion. It is therefore possible that this dose encountered mostly resting pumps, which it was unable to inhibit. At bedtime, the proton pumps are in a stage of renewing. This means that the quantity of active pumps is fewer than during the day, and thus that the function of PPI is weaker than during the day (<LINK REF="REF-Hongo-1992" TYPE="REFERENCE">Hongo 1992</LINK>; <LINK REF="REF-Maton-1991" TYPE="REFERENCE">Maton 1991</LINK>; <LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>).</LI>
<LI>A combination of histaminergic and vagal stimuli seems most likely to be involved in this acid breakthrough (<LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>).</LI>
<LI>The absence of <I>Helicobacter pylori</I> is reported to increase the prevalence of NAB, which has been observed mainly in cases without H. pylori infection (<LINK REF="STD-Katsube-2000" TYPE="STUDY">Katsube 2000</LINK>; <LINK REF="REF-Van-Herwaarden-2000" TYPE="REFERENCE">Van Herwaarden 2000</LINK>).</LI>
<LI>Some studies have found that the acid inhibitory effect of PPI depends on S-mephenytoin 4-hydroxylase (CYP2C19) genotype status. The frequency of NAB was greater in homozygous extensive metabolisers during the administration of lansoprazole (<LINK REF="REF-Furuta-2001" TYPE="REFERENCE">Furuta 2001</LINK>; <LINK REF="REF-Shirai-2002" TYPE="REFERENCE">Shirai 2002</LINK>).</LI>
</OL>
</CONDITION>
<INTERVENTION MODIFIED="2009-08-04 11:15:28 +0100" MODIFIED_BY="Cathy Bennett">
<P>H<SUB>2</SUB>-receptor antagonists (H2RAs) have also been used for the treatment of acid-related diseases for more than a decade. The overall acid inhibitory effects of H2RAs have been considered to be less than those of PPI. However, recent studies have found that adding H2RAs at bedtime to high dose PPI can enhance nocturnal gastric pH control, decrease nocturnal gastric acid breakthrough, and decrease the duration of oesophageal acid reflux associated with NAB (<LINK REF="STD-Katsube-2000" TYPE="STUDY">Katsube 2000</LINK>; <LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>). In addition, bedtime PPI administration on PPI twice-daily treatment is reported to not be effective for the control of NAB (<LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>).<BR/>
</P>
</INTERVENTION>
<THEORY MODIFIED="2009-08-04 11:18:15 +0100" MODIFIED_BY="Cathy Bennett">
<P>The effectiveness of bedtime H2RAs is probably because histamine plays a major role in NAB and the acid inhibitory effects of H2RAs are not influenced by CYP2C19 genotype status (<LINK REF="REF-Furuta-2001" TYPE="REFERENCE">Furuta 2001</LINK>). However, another trial found that the combination of H2RAs and PPI therapy reduced NAB only with the introduction of therapy. Because of H2RAs tolerance, there is no difference in acid suppression between PPI twice daily and PPI twice daily + H2RAs after one week of combination therapy (<LINK REF="STD-Fackler--2002" TYPE="STUDY">Fackler 2002</LINK>).<BR/>
</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-08-04 11:15:28 +0100" MODIFIED_BY="Cathy Bennett">
<P>No consistent conclusion has been reported from individual studies evaluating H2RAs for the control of NAB. The effectiveness and quality of such treatment needs to be reviewed systematically and appraised critically to inform the current practice and direct the continued search for new treatment regimens.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-08-04 11:15:28 +0100" MODIFIED_BY="Cathy Bennett">
<P>To assess the effectiveness of addition bedtime H2RAs in suppressing nocturnal gastric acid breakthrough and the incidence of adverse effects.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-10 15:29:36 +0100" MODIFIED_BY="Cathy Bennett">
<SELECTION_CRITERIA MODIFIED="2009-08-04 11:29:21 +0100" MODIFIED_BY="Cathy Bennett">
<CRIT_STUDIES MODIFIED="2009-08-04 11:18:31 +0100" MODIFIED_BY="Cathy Bennett">
<P>All randomized controlled trials evaluating H2-receptor antagonists for the control of NAB were eligible for inclusion. We included trials irrespective of the language in which they were reported.<BR/>
</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-08-04 11:15:28 +0100" MODIFIED_BY="Cathy Bennett">
<P>Nocturnal gastric acid breakthrough (NAB) was defined as intragastric pH&lt;4 for more than one continuous hour overnight. The participants included normal volunteers, GERD participants and peptic ulcer participants.</P>
<P>Because patients with duodenal ulcer have a higher acid secretion than normal and GERD patients, and also maintain a more sustained response to acid suppression with H2RAs, We intended to sub-group trials according to the different populations studied. However, no trials studying duodenal ulcer met our inclusion criteria.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-08-04 11:29:21 +0100" MODIFIED_BY="Cathy Bennett">
<P>Additional bedtime H2RAs (cimetidine, famotidine, nizatidine and ranitidine) administered with PPI (esopremazole, lansoprazole, omeprazole, pantoprazole and rabeprazole) once daily or twice daily.</P>
<P>The tested H2RAs regimens that fell under one of the following dosage levels were included in this review:</P>
<OL>
<LI>cimetidine 200mg or 400mg or 800mg;</LI>
<LI>famotidine 10mg or 20mg or 40mg;</LI>
<LI>nizatidine 75mg or 150mg;</LI>
<LI>ranitidine 75mg or 150mg or 300mg.</LI>
</OL>
<P>We originally intended that sub-group trials should be sub-grouped according to the duration of medication actually used, regardless of how long H2RAs were used:</P>
<OL>
<LI>short-term: duration&lt; 4 weeks;</LI>
<LI>long-term: duration&gt;= 4 weeks.</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-02-09 11:04:29 +0000" MODIFIED_BY="Cathy Bennett">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-02-09 11:04:18 +0000" MODIFIED_BY="Cathy Bennett">
<P>Prevalence rate of nocturnal gastric acid breakthrough.<BR/>
</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-02-09 11:04:29 +0000" MODIFIED_BY="Cathy Bennett">
<OL>
<LI>Percentage of time during which pH is less than 4.0 inside the stomach.</LI>
<LI>Median intragastric pH.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-10 15:29:36 +0100" MODIFIED_BY="Cathy Bennett">
<ELECTRONIC_SEARCHES MODIFIED="2009-07-01 13:53:00 +0100" MODIFIED_BY="Cathy Bennett">
<P>We identified eligible trials by searching MEDLINE January 1966 to August 2008, EMBASE January 1980 to August 2008, Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2008) and CINAHL 1982 to August 2008. We did not confine our search to English language publications. Searches in all databases were conducted in July 2003 and updated in June 2004, July 2005, August 2006 and August 2008.<BR/>
<BR/>The Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE, sensitivity maximising version, Ovid format (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). was combined with the following search terms to identify randomized controlled trials in MEDLINE. The MEDLINE search strategy was adapted for use in the other databases searched.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-08-10 15:29:36 +0100" MODIFIED_BY="Cathy Bennett">
<P>We also handsearched reference lists from trials selected by electronic searching to identify further relevant trials, as well as published abstracts from the conference proceedings of the American Digestive Disease Week (DDW) (published in Gut) and the United European Gastroenterology Week (UEGW) (published in Gastroenterology).</P>
<P>Some Chinese journals were also handsearched (Chinese Journal of Digestion,Chinese Journal of Digestion Endoscopy, World Chinese Journal of Digestology, Chinese Journal of Gastroenterology and Hepatology, Journal of Clinical Internal Medicine, Chinese Journal of Pratical Internal Medicine) from January 1998 to January 2009.<BR/>
</P>
<P>We also contacted members of the Cochrane UGPD Group and experts in the field of gastroenterology and requested information concerning any outstanding clinical trials and relevant unpublished materials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-04 11:30:27 +0100" MODIFIED_BY="Cathy Bennett">
<STUDY_SELECTION MODIFIED="2009-07-22 11:47:24 +0100" MODIFIED_BY="Cathy Bennett">
<P>One author evaluated papers identified by the initial searches and excluded any which were unrelated to this review. Decisions at this stage were made based upon the title and abstract (if available). A second author independently checked a sample of these papers. Two reviewers made inclusion decisions independently, according to the pre-stated eligibility criteria. The authors recorded inclusion decisions on specially developed forms; they reviewed disagreements, and consulted a third reviewer for any that required resolution.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-08-04 11:29:57 +0100" MODIFIED_BY="Cathy Bennett">
<P>Wang Qiong and Zhen Guo independently performed the data extraction. One reviewer extracted data and a second reviewer checked data extraction. We also double-checked data entry into RevMan. We extracted the following data from the included trials and recorded relevant information on to specially developed forms.</P>
<P>We recorded data on the following features:</P>
<OL>
<LI>country of origin;</LI>
<LI>method of randomisation (true versus pseudo; stated versus not stated);</LI>
<LI>adequacy of allocation concealment: adequate (A), unclear (B), inadequate (C), not used (D);</LI>
<LI>details of blinding of participants and outcome assessors: stated versus not stated, masked versus not masked;</LI>
<LI>inclusion and exclusion criteria used;</LI>
<LI>baseline comparability between treatment groups;</LI>
<LI>treatments compared and number of participants in each arm;</LI>
<LI>dropouts reported and their reasons;prevalence rate of nocturnal gastric acid breakthrough;</LI>
<LI>percentage of time which pH is less than 4.0 inside the stomach;</LI>
<LI>median intragastric pH; </LI>
<LI>type of drugs; </LI>
<LI>dose of drugs;</LI>
<LI>name of drugs;</LI>
<LI>schedules of drugs;</LI>
<LI>H. pylori infection status;</LI>
<LI>adverse events: the total number reported.</LI>
</OL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-08-04 11:30:27 +0100" MODIFIED_BY="Cathy Bennett">
<P>Methodological quality will be defined as the confidence that the design and report restrict bias in the intervention comparison (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>). The methodological quality was assessed by four separate components, that is, adequacy of generation of the allocation sequence, allocation concealment, double blinding, and follow-up (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>) according to the following:</P>
<SUBSECTION>
<HEADING LEVEL="4">Generation of the allocation sequence</HEADING>
<P>A. Adequate, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice may also be considered as adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure.<BR/>B. Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described.<BR/>C. Inadequate, if a system involving dates, names, or admittance numbers was used for the allocation of participants (that is, quasi-randomisation).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>A. Adequate, if the allocation of participants involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes. Envelopes should be serially numbered, sealed, and opaque. However, this information is rarely provided, indicating an increased risk of bias. In that participant, sealed envelopes may constitute an intermediate category between adequate and unclear.<BR/>B. Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described.<BR/>C. Inadequate, if the allocation sequence was known to the investigators who assigned participants or if the trial was quasi-randomised.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding (or masking )</HEADING>
<P>A. Adequate, if the trial was described as double blind and the method of blinding involved identical placebo or active drugs.<BR/>B. Unclear, if the trial was described as double blind, but the method of blinding was not described.<BR/>C. Not performed, if the trial was not double blind.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Follow-up</HEADING>
<P>A. Adequate, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals.<BR/>B. Unclear, if the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.<BR/>C. Inadequate, if the number or reasons for dropouts and withdrawals were not described.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-07-28 13:20:26 +0100" MODIFIED_BY="[Empty name]">
<P>All analyses were performed according to the intention-to-treat principle including all randomised participants, participants without outcome variables were considered treatment failures ('worst-participant scenario analysis').</P>
<P>For binary outcomes, such as the presence or absence of symptoms, the impact of the intervention was expressed as relative risk (RR) together with 95% confidence intervals. For continuous outcomes, means and standard deviations were used to summarise the value in each group. Weighted mean difference or standardised mean differences for continuous outcomes were used depending on whether the continuous data used the same scale or not.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-07-28 10:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>We used data from the first period of cross over trials in the analyses.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-07-22 14:19:38 +0100" MODIFIED_BY="Cathy Bennett">
<P>The authors of the trials were approached to specify any data that they had not sufficiently reported in the article as follows:</P>
<UL>
<LI>Trial characteristics.</LI>
<LI>Methodological quality.</LI>
<LI>Whether the trial used a parallel or crossover design.</LI>
<LI>Number of intervention arms.</LI>
<LI>Length of follow-up.</LI>
<LI>Estimation of sample size.</LI>
<LI>Use of intention-to-treat analyses.</LI>
<LI>Patient characteristics</LI>
<LI>Number of participants randomised to each intervention arm, mean (or median) age, number of males and females, type of digestive disease, inclusion and exclusion criteria, etc.</LI>
<LI>Intervention characteristics</LI>
<LI>Dose of intervention, duration of therapy, and mode of administration.</LI>
<LI>Type and dose of additional interventions.</LI>
</UL>
</MISSING_DATA>
<BIAS_ASSESSMENT MODIFIED="2009-07-01 14:03:33 +0100" MODIFIED_BY="Cathy Bennett">
<P>Funnel plot asymmetry was estimated by regression analysis (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-07-22 11:58:02 +0100" MODIFIED_BY="Cathy Bennett">
<P>For binary outcomes, we expressed the impact of the intervention was as relative risks (RR), together with 95% confidence intervals. For scale-based outcomes, we used means and standard deviations to summarise the values in each group, provided the scale permitted sufficient values. We conducted meta-analyses by the random effects model or the fixed effect model according whether to the heterogeneity is significant or not. However, we will only report the results of the random effects model analyses unless the results of the two models differed (one significant, the other insignificant). In the latter case we will report both model analyses.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-07-22 14:33:42 +0100" MODIFIED_BY="Cathy Bennett">
<P>Subgroup analyses were used to explore the association between dose and duration of experimental interventions and effect.</P>
<P>If future updates of this review provide sufficient data, we will compare subgroups of trials to examine the association between disease severity at entry and effect; and also explore the effect of including studies with and without adequate methodological components (generation of allocation sequence, allocation concealment, blinding, follow-up) with respect to primary outcome measures.</P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-08-04 11:21:41 +0100" MODIFIED_BY="Cathy Bennett">
<STUDY_DESCRIPTION MODIFIED="2009-08-04 11:21:41 +0100" MODIFIED_BY="Cathy Bennett">
<SEARCH_RESULTS MODIFIED="2009-07-22 14:12:24 +0100" MODIFIED_BY="Cathy Bennett">
<P>We got 45 references drawn from the electronic search results, of which one was a comment, one was a case report and 16 were reviews. The remaining 27 trials were evaluated.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-08-04 11:21:41 +0100" MODIFIED_BY="Cathy Bennett">
<P>We identified only 8 trials that satisfied the inclusion criteria (see the table, '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>', for more information). Participants in these studies received all interventions in a random order (<LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>; <LINK REF="STD-Khoury-1999" TYPE="STUDY">Khoury 1999</LINK>; <LINK REF="STD-Bing-2005" TYPE="STUDY">Bing 2005</LINK>; <LINK REF="STD-Cong-2004" TYPE="STUDY">Cong 2004</LINK>; <LINK REF="STD-Cong-2004b" TYPE="STUDY">Cong 2004b</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>; <LINK REF="STD-Jun-2005" TYPE="STUDY">Jun 2005</LINK>), and both the two studies were a cross-over design.</P>
<P>In <LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>, twelve healthy, asymptomatic volunteers were pre-treated with 20mg oral omeprazole twice daily for seven days. Beginning on day eight, participants received additional treatments with placebo, 150mg ranitidine, 300mg ranitidine and an additional 20mg dose of omeprazole at bedtime. The length of treatment was only one day. The author did not mentioned washout time, but noted that all four studies were completed over the following four to 21 days.The <I>Helicobacter pylori</I> status of the participants was assessed by serology, all participants were negative.</P>
<P>
<LINK REF="STD-Khoury-1999" TYPE="STUDY">Khoury 1999</LINK> gave 20 healthy asymptomatic volunteers 20mg omeprazole before breakfast and before dinner, with placebo at bedtime for seven days. Alternatively, participants received 20mg omeprazole before breakfast, placebo before dinner and 150mg ranitidine at bedtime for seven days. The length of treatment was seven days. The washout time was one week. Fifteen participants were negative and five participants were positive for <I>Helicobacter pylori</I> .</P>
<P>In <LINK REF="STD-Bing-2005" TYPE="STUDY">Bing 2005</LINK>, 30 GERD participants, mean age of 35 years were participated; their <I>Helicobacter pylori</I> status was negative. Both intervention group and control group have15 cases. The intervention group received 20mg omeprazole before breakfast and before dinner with 40mg famotidine at bedtime; the control group received 20mg omeprazole before breakfast and before dinner. The length of treatment was seven days.</P>
<P>In <LINK REF="STD-Cong-2004" TYPE="STUDY">Cong 2004</LINK>, 40 duodenal ulcer participants, mean age of 56.2 years were participated; their <I>Helicobacter pylori</I> status was positive. Both of the 2 intervention groups and 2 control groups had10 participants The intervention group 1 received 20mg omeprazole before breakfast and before dinner with 20mg famotidine at bedtime; the control group1 received 20mg omeprazole before breakfast and before dinner. The intervention group 2 received 20mg omeprazole before breakfast with 20mg famotidine at bedtime; the control group 2 received 20mg omeprazole before breakfast.The length of treatment was 5 days.</P>
<P>In <LINK REF="STD-Cong-2004b" TYPE="STUDY">Cong 2004b</LINK>, 32 duodenal ulcer participants, mean age of 66.1 years were participated; their <I>Helicobacter pylori</I> status was positive. Both 2 intervention groups and 2 control groups had10 cases. The intervention group 1 received 20mg omeprazole before breakfast and before dinner with 20mg famotidine at bedtime; the control group 1 received 20mg omeprazole before breakfast and before dinner. The intervention group 2 received 20mg omeprazole before breakfast with 20mg famotidine at bedtime; the control group 2 received 20mg omeprazole before breakfast.The length of treatment was 5 days.</P>
<P>In <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>, 44 duodenal ulcer participants, mean age of 45 years participated; their <I>Helicobacter pylori</I> status was positive. Both 2 intervention groups and 2 control groups had 11 cases. The intervention group 1 received 20mg omeprazole before breakfast with 150mg ranitidine at bedtime; the control group 1 received 20mg omeprazole before breakfast. The intervention group 2 received 20mg omeprazole before breakfast and before dinner with 150mg ranitidine at bedtime; the control group 2 received 20mg omeprazole before breakfast and before dinner.The length of treatment was 5 days.</P>
<P>In <LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>, 14 participants with systemic sclerosis and GERD symptoms, mean age of 61.7 years participated. Only 1 patient's <I>Helicobacter pylori</I> status was positive. participants were treated with omeprazole 20 mg b.i.d and either placebo or ranitidine 300 mg at bedtime for 6 weeks in a randomized, cross-over, placebo controlled study. At the end of each period a 24h pH-study with intragastric and oesophageal pH measurement was performed.</P>
<P>In <LINK REF="STD-Jun-2005" TYPE="STUDY">Jun 2005</LINK>, 20 duodenal ulcer participants, mean age of 38.6 years participated. <I>Helicobacter pylori</I> status was negative. Both intervention group and control group had 10 cases. The intervention group received 20mg omeprazole before breakfast with 40mg famotidine at bedtime; the control group received 20mg omeprazole before breakfast and before dinner. The length of treatment was seven days.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-08-04 11:15:28 +0100" MODIFIED_BY="Cathy Bennett">
<P>We excluded 19 studies (see the table, '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>', for more information). Two studies were retrospective controlled trials and six studies were non-randomized controlled trials. Three randomized controlled trials comparing the efficacy of daytime PPI and single nighttime H2RAs were excluded (<LINK REF="STD-Judmaier-1994" TYPE="STUDY">Judmaier 1994</LINK>; <LINK REF="STD-Brummer-1996" TYPE="STUDY">Brummer 1996</LINK>; <LINK REF="STD-Van-Zyl-2000" TYPE="STUDY">Van Zyl 2000</LINK>). One randomized controlled trial assessing daytime intragastric pH control of proton pump inhibitors on the day after night-time or early morning H2RAs was also excluded (<LINK REF="STD-Tutuian-2002" TYPE="STUDY">Tutuian 2002</LINK>). Two retrospective controlled trials assessed the effectiveness of PPI twice daily plus bedtime H2RAs comparing PPI twice daily in suppressing nocturnal gastric acid breakthrough (<LINK REF="STD-Shuwen--2000" TYPE="STUDY">Shuwen 2000</LINK>; <LINK REF="STD-Xue-2001" TYPE="STUDY">Xue 2001</LINK>). Three non-randomized studies evaluated long-term effect of H2RAs therapy on nocturnal gastric acid breakthrough (<LINK REF="STD-Fackler-2000" TYPE="STUDY">Fackler 2000</LINK>; <LINK REF="STD-Fackler--2002" TYPE="STUDY">Fackler 2002</LINK>; <LINK REF="STD-Tina-2003" TYPE="STUDY">Tina 2003</LINK>); one non-randomized study compared morning dose of rabeprazole and additional bedtime H2RAs to morning or evening dose of rabeprazole (<LINK REF="STD-Katsube-2000" TYPE="STUDY">Katsube 2000</LINK>); and one non-randomized study compared morning dose of omeprazole, omeprazole twice daily and low dose bedtime ranitidine to supplement daily omeprazole (<LINK REF="STD-Robinson-2002" TYPE="STUDY">Robinson 2002</LINK>).The aim of one study (<LINK REF="STD-JianQiang-2005" TYPE="STUDY">JianQiang 2005</LINK>) was to compare the efficacy of rabeprazole and esomeprazole.The intervention in <LINK REF="STD-Keshang-2005" TYPE="STUDY">Keshang 2005</LINK> is famotidine plus other drugs.The participants in <LINK REF="STD-Pfefferkorn-2006" TYPE="STUDY">Pfefferkorn 2006</LINK> were children, the regimen of the intervention is different from our protocol.The aim of <LINK REF="STD-Shimatani-2006" TYPE="STUDY">Shimatani 2006</LINK> study was to compare the efficacy of lafutidine and famotidine.The aim of <LINK REF="STD-Sugimoto-2005" TYPE="STUDY">Sugimoto 2005</LINK> study was to assess how participants of different genotypes react to drugs; there were no eligible outcomes reported. The aim of <LINK REF="STD-Warrington-2007" TYPE="STUDY">Warrington 2007</LINK> study was to compare the efficacy of rabeprazole 20 mg and pantoprazole 40 mg in participants with GERD and nocturnal heartburn. The aim of <LINK REF="STD-Xiaohui-2005" TYPE="STUDY">Xiaohui 2005</LINK> study was to assess the healing rate of RE; there were no eligible outcomes reported.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett">
<P>See table, '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>', risk of bias tables.</P>
<P>The methods used for randomization or allocation concealment were not well described in any study. 3 studies (<LINK REF="STD-Khoury-1999" TYPE="STUDY">Khoury 1999</LINK>; <LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>; <LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>) mentioned double-blinding, but it was not clear what this referred to. In one study (<LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>) 4 drop-outs occurred, but the trials investigators did not mention the reason why these participants did not complete the follow-up period.<BR/>All the included studies reported inclusion criteria, but only 2 studies (<LINK REF="STD-Bing-2005" TYPE="STUDY">Bing 2005</LINK>; <LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>) had exclusion criteria. No study reported adverse events. Both studies took baseline assessments, 3 studies (<LINK REF="STD-Cong-2004" TYPE="STUDY">Cong 2004</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Cong-2004b" TYPE="STUDY">Cong 2004b</LINK>) conducted the comparability between groups. Only 1 study (<LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>) measured the long-term effects of H2RAs. The duration of H2RAs used in the other studies was less than four weeks.</P>
<ALLOCATION MODIFIED="2009-07-22 12:38:16 +0100" MODIFIED_BY="Cathy Bennett">
<P>Only 1 included study (<LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>) mentioned that the allocation sequences were generated by "sortition", the other studies did not mentioned how allocation sequences were generated.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-07-22 12:34:27 +0100" MODIFIED_BY="Cathy Bennett">
<P>3 included studies (<LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>; <LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>; <LINK REF="STD-Khoury-1999" TYPE="STUDY">Khoury 1999</LINK>) were double-blind studies, the other studies were not performed as blind studies.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-07-22 14:57:42 +0100" MODIFIED_BY="Cathy Bennett">
<P>All the included studies reported the prevalence rate of nocturnal gastric acid breakthrough. 7 included studies (<LINK REF="STD-Bing-2005" TYPE="STUDY">Bing 2005</LINK>; <LINK REF="STD-Cong-2004" TYPE="STUDY">Cong 2004</LINK>; <LINK REF="STD-Cong-2004b" TYPE="STUDY">Cong 2004b</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Jun-2005" TYPE="STUDY">Jun 2005</LINK>; <LINK REF="STD-Khoury-1999" TYPE="STUDY">Khoury 1999</LINK>; <LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>) reported the percentage of time during which pH is less than 4.0 inside the stomach, but 5 studies (<LINK REF="STD-Bing-2005" TYPE="STUDY">Bing 2005</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Jun-2005" TYPE="STUDY">Jun 2005</LINK>; <LINK REF="STD-Khoury-1999" TYPE="STUDY">Khoury 1999</LINK>; <LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>) used the median to report the outcome data, so we could not extract data for meta-analysis. 5 included studies (<LINK REF="STD-Cong-2004" TYPE="STUDY">Cong 2004</LINK>; <LINK REF="STD-Cong-2004b" TYPE="STUDY">Cong 2004b</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>; <LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>) reported median intragastric pH, but 2 studies (<LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>; <LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>) used the median to report the outcome data, so we could not extract data for meta-analysis.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett">
<P>Only one study measured the long-term effects of H2RAs (<LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-07-22 12:29:58 +0100" MODIFIED_BY="Cathy Bennett">
<P>No study reported adverse events.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett">
<SUBSECTION>
<HEADING LEVEL="3">H2RAs versus control</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Prevalence rate of nocturnal gastric acid breakthrough</HEADING>
<P>We extracted data from 8 small randomized controlled trials (<LINK REF="STD-Bing-2005" TYPE="STUDY">Bing 2005</LINK>; <LINK REF="STD-Cong-2004" TYPE="STUDY">Cong 2004</LINK>; <LINK REF="STD-Cong-2004b" TYPE="STUDY">Cong 2004b</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>; <LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>; <LINK REF="STD-Jun-2005" TYPE="STUDY">Jun 2005</LINK>; <LINK REF="STD-Khoury-1999" TYPE="STUDY">Khoury 1999</LINK>; <LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>),137 participants in the intervention group and 137 participants in the control group were included for meta-analysis.The heterogeneity was significantly different between the included studies (P=0.02), so we chose a random effects analysis model (RR 0.48; 95% CI 0.30 to 0.75); <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).The results show that additional bedtime H2RAs can decrease the prevalence rate of nocturnal gastric acid breakthrough.</P>
<P>We carried out sub-group analyses. In the short-term group, 7 trials included 127 participants in the intervention group and 127 participants in the control group were included for meta-analysis.The heterogeneity was significant different between the included studies (P=0.01), so we chose a random effects analysis model (RR(0.43; 95% CI 0.25 to 0.72]).The result show that in short-term group additional bedtime H2RAs can decrease the prevalence rate of nocturnal gastric acid breakthrough. In long-term group, only 1 trial was included with 10 participants in the intervention group and 10 participants in the control group. The results show that in long-term group additional bedtime H2RAs have no significant difference in the prevalence rate of nocturnal gastric acid breakthrough compare with control group (RR 0.75; 95% CI 0.41 to 1.36; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Percentage of time during which pH is less than 4.0 inside the stomach</HEADING>
<P>Only 2 randomized controlled trials (<LINK REF="STD-Cong-2004" TYPE="STUDY">Cong 2004</LINK>; <LINK REF="STD-Cong-2004b" TYPE="STUDY">Cong 2004b</LINK>) provided data that we could extract for meta-analysis. Thirty-six participants in the intervention group and 36 participants in the control group were included for meta-analysis.As the heterogeneity was not significantly different between the included studies (P=0.11), we chose a fixed effects analysis model (MD -10.41; 95% CI -12.51 to -8.30; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The result shows that additional bedtime H2RAs can decrease the percentage of time during which pH is less than 4.0 inside the stomach.</P>
<P>No randomized controlled trial provided useful information of long-term additional bedtime H2RAs on the percentage of time during which pH is less than 4.0.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Median intragastric pH</HEADING>
<P>Only 3 randomized controlled trials (<LINK REF="STD-Cong-2004" TYPE="STUDY">Cong 2004</LINK>; <LINK REF="STD-Cong-2004b" TYPE="STUDY">Cong 2004b</LINK>; <LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>) provided data that we could extract for meta-analysis. Fifty eighty participants in the intervention group and 58 participants in the control group were included for meta-analysis.The heterogeneity was significantly different between the included studies (P&lt;0.0001), so we chose a random effects analysis model. The results show that additional bedtime H2RAs can promote an elevation in the median intragastric pH (MD 1.22; 95% CI 0.78 to 1.65; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other secondary outcomes</HEADING>
<P>No randomized controlled trial provided useful information of long-term outcomes.</P>
<P>None of the included studies trials reported adverse events.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-08-04 13:30:38 +0100" MODIFIED_BY="Cathy Bennett">
<SUMMARY_OF_RESULTS MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett">
<P>Eight small randomized controlled trials, including 137 participants in the intervention group and 137 participants in the control group were included for meta-analysis. The results show that additional bedtime H2RAs can decrease the prevalence rate of nocturnal gastric acid breakthrough; sub-group analysis found that the result of short-term group was consistent with the total study meta-analysis. In the long-term group, only 1 trial was included, it showed that in partcipants given long-term additional bedtime H2RAs, there was no significant difference in the prevalence rate of nocturnal gastric acid breakthrough compare with control group. The results of secondary outcome analyses show that additional bedtime H2RAs can decrease the percentage of time during which pH is less than 4.0 inside the stomach and the results show that additional bedtime H2RAs can promote an elevation in the the median intragastric pH, but no randomized controlled trial provided useful information for long-term sub-group analysis.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-08-04 13:30:38 +0100" MODIFIED_BY="Cathy Bennett">
<P>Nocturnal acid breakthrough is of clinical importance because of the potential for gastroesophageal reflux during this time period when the esophageal protective mechanisms of saliva production and esophageal motility are decreased, such that further esophageal mucosa damage may occur, therefore, worsening the underlying GERD. Extra-esophageal manifestation may also develop. Maintenance of intragastric pH &gt; 4 is a reasonable and rational objective of PPI therapy, and has been previously shown to correlate significantly with ability to effect healing of erosive oesophagitis (<LINK REF="REF-Bell-1992" TYPE="REFERENCE">Bell 1992</LINK>). The rationale of adding H2RAs to PPI therapy stems from the fact that maximal benefit from PPI therapy is derived only when given 15&#8211;30 min before meals, such that the optimal blood concentration is reached at the time of meal-induced activation of proton pumps. During night-time, since there is no food ingestion, adjunctive H2RAs therapy at bedtime may be potentially more useful for acid suppression. Our review found that additional bedtime H2RAs can decrease the prevalence rate of nocturnal gastric acid breakthrough (RR 0.48; 95% CI 0.30 to 0.75), but sub-group analysis gave inconsistent results. In the short-term group the prevalence rate of nocturnal gastric acid breakthrough was significantly decreased (RR 0.43; 95% CI 0.25 to 0.72; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) but in the long-term group, additional bedtime H2RAs did not improve NAB. Only 1 small trial (<LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>) was included in the long-term group. The participants in this trial were participants with systemic sclerosis and GERD symptoms, the clinical characteristics were different from other GERD participants because systemic sclerosis is a systemic disease, the treatment is more complicated, and the results should be interpreted cautiously. The results of secondary outcome analysis show that additional bedtime H2RAs can decrease the percentage of time during which pH is less than 4.0 inside the stomach (MD -10.41; 95% CI -12.51 to -8.30; <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) and the results show that additional bedtime H2RAs can promote an elevation in the median intragastric pH (MD 1.22; 95% CI 0.78 to 1.65; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>); only 3 trials provided useful data for this outcomes that could be used for meta-analysis. Some studies show the result by other means. The study of Peghini (<LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>) indicated that additional omeprazole at bedtime reduced the percentage of time with intragastric pH of &lt;4 from 48% to 31%, compared with omeprazole twice daily with placebo at bedtime. Ranitidine at bedtime reduced this measure even more, by 5% with 150mg and 6% with 300mg. Median intragastric pH values for the 8-hour overnight period were 4.2 (IQR, 2.9-5.0) for omeprazole twice daily with placebo at bedtime; 5.7 (IQR, 5.0-6.4) for the regimen with three doses of omeprazole (P&lt;0.005 versus placebo); and 7.2 (IQR, 6.3-7.4) and 7.2 (IQR, 6.9-7.4) for 150mg and 300mg ranitidine, respectively, in addition to omeprazole twice daily (P&lt;0.001 versus placebo and versus additional omeprazole). <LINK REF="STD-Khoury-1999" TYPE="STUDY">Khoury 1999</LINK> indicated that recumbent time pH&lt;4 on 20mg omeprazole bid was 23.45 compared to 44.75 on omeprazole qd plus ranitidine. <LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK> indicated that median intragastric pH in the 10-h nocturnal period were similar during both treatment regimens, and there were no significant differences in mean gastric pH during the 10-h nocturnal study period and the full 24-h period in the placebo (pH 4.5; 3.1&#8211;6.6 vs. pH 4.9;3.2&#8211;6.1) or ranitidine (pH 4.3; 1.7&#8211;7.0 vs. pH 4.4; 1.8&#8211;7.0) study arms. The duration of <LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK> was 6 weeks, but because of the special participants, we can only draw limited conclusion from this trial.</P>
<P>No study fully documented the possible development of H2RA tolerance, and the long-term efficacy of H2RAs is important. The only available long-term study is <LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK> and the available evidence is therefore limited.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-07-28 10:15:58 +0100" MODIFIED_BY="[Empty name]">
<P>Only 8 randomized controlled trials were included in the study, all included trials were small, the overall participants were only 137 in the intervention group and 137 in the control group. The allocation concealment in all the included trials was unclear, only 3 trials (<LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK>; <LINK REF="STD-Khoury-1999" TYPE="STUDY">Khoury 1999</LINK>; <LINK REF="STD-Peghini-1998b" TYPE="STUDY">Peghini 1998b</LINK>) performed double-blinding. Only 1 trial (<LINK REF="STD-Hong-2002" TYPE="STUDY">Hong 2002</LINK>) reported that the generation of allocation sequence by "sortition", the generation of allocation sequence in all other trials was unclear. Follow up in 7 trials was unclear, in 1 trial (<LINK REF="STD-Janiak--2007" TYPE="STUDY">Janiak 2007</LINK> ) follow up was inadequate. The overall quality of the evidence was poor.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-06-18 15:31:37 +0100" MODIFIED_BY="[Empty name]">
<P>None known.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett">
<P>The results show that additional bedtime H2RAs can decrease the prevalence rate of nocturnal gastric acid breakthrough; this finding was supported by a non-randomised controlled trial (<LINK REF="STD-Katsube-2000" TYPE="STUDY">Katsube 2000</LINK>) investigating the prevalence of NAB in Japanese subjects treated with rabeprazole and H2RAs .Three non-randomized studies (<LINK REF="STD-Fackler-2000" TYPE="STUDY">Fackler 2000</LINK>; <LINK REF="STD-Fackler--2002" TYPE="STUDY">Fackler 2002</LINK>; <LINK REF="STD-Tina-2003" TYPE="STUDY">Tina 2003</LINK>) evaluated long-term effect of H2RAs therapy on nocturnal gastric acid breakthrough. Two trials (<LINK REF="STD-Fackler-2000" TYPE="STUDY">Fackler 2000</LINK>; <LINK REF="STD-Fackler--2002" TYPE="STUDY">Fackler 2002</LINK>) found that the effect of nocturnal gastric acid reduction with H2RAs was minimal and lessens with prolonged therapy. These two trials are before-after studies and included both healthy volunteers and GERD participants. One trial (<LINK REF="STD-Tina-2003" TYPE="STUDY">Tina 2003</LINK>) found that no single treatment regimen resulted in more significant NAB suppression than the others. This study included 13 individuals symptomatic for GERD in the treatment group and nine healthy volunteers as controls. The baseline was not equivalent in the two groups.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-08-04 11:27:11 +0100" MODIFIED_BY="Cathy Bennett">
<IMPLICATIONS_PRACTICE MODIFIED="2009-08-04 11:27:11 +0100" MODIFIED_BY="Cathy Bennett">
<P>Based on this systematic review, it appeared that additional bedtime H2RAs can decrease the prevalence rate of nocturnal gastric acid breakthrough, the percentage of time during which pH is less than 4.0 inside the stomach and promote an elevation in the median intragastric pH. However, due to the low methodological quality of the RCTs and inadequate clinical data, there are no implications for practice at this stage. Furthermore, evidence of long-term efficacy of H2RAs is lacking; and side effects have not yet been reported. We therefore believe that additional bedtime H2RAs to PPI should only be used as an intervention in randomized trials until further evidence has been found.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett">
<P>More randomized controlled trial data are needed to determine the effects of additional bedtime H2RAs to PPI in suppressing nocturnal gastric acid breakthrough. Many clinical trials that we investigated reported only the short-term effect of additional bedtime H2RAs to PPI. The long-term effects of H2RAs, when given continuously, should be investigated. For example, investigators could record at one or two months how the participants were responding to the medicine. Appropriately designed parallel group, randomized controlled trials with long-term follow-up are needed to confirm the effect of additional bedtime H2RAs in suppressing nocturnal gastric acid breakthrough.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-07-22 14:26:30 +0100" MODIFIED_BY="Cathy Bennett">
<P>Dr Cathy Bennett, Janet Lilleyman (Managing editor), and Iris Gordon (Trials Search Co-ordinator), of the Cochrane Upper Gastrointestinal and Pancreatic Group, were of invaluable help throughout the review and we are most grateful to them for their advice and support.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Pan Tao wrote the review, which was checked and authorised by Dr Yiping Wang. Wang Qiong and Zhen Guo helped to extract the data.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-08-04 13:41:15 +0100" MODIFIED_BY="Cathy Bennett">
<STUDIES MODIFIED="2009-07-28 10:17:30 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-07-22 13:41:13 +0100" MODIFIED_BY="Cathy Bennett">
<STUDY DATA_SOURCE="PUB" ID="STD-Bing-2005" MODIFIED="2009-06-13 03:19:12 +0100" MODIFIED_BY="[Empty name]" NAME="Bing 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-13 03:19:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bing W, Shaoyong X, Yong D, Jun S</AU>
<TI>The relationship and clinical meaning of nocturnal gastric acid breakthrough and acid exposure of esophagus</TI>
<SO>New Chinese Medicine</SO>
<YR>2005</YR>
<VL>36</VL>
<NO>2</NO>
<PG>79-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cong-2004" MODIFIED="2009-07-22 13:07:52 +0100" MODIFIED_BY="Cathy Bennett" NAME="Cong 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-07-22 13:07:52 +0100" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cong L, You J, Ruxin L, Chunmeng J, Miaona J, Yujie J</AU>
<TI>Clinical investigation into nocturnal acid breakthrough in patients with duodenal ulcer</TI>
<SO>Chinese Journal of Practical Internal Medicine.</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>12</NO>
<PG>725-727</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cong-2004b" MODIFIED="2009-07-01 14:22:42 +0100" MODIFIED_BY="Cathy Bennett" NAME="Cong 2004b" YEAR="2004">
<REFERENCE MODIFIED="2009-06-13 04:14:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cong L, You J, Miaona J, Shanhong Z, Yanjin L, Chunmeng J, Yujie J</AU>
<TI>Clinical study of nocturnal acid breakthrough in old patients with duonenal ulcer</TI>
<SO>World Chinese Journal of Digestology</SO>
<YR>2004</YR>
<VL>12</VL>
<NO>10</NO>
<PG>2514-2517</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-2002" MODIFIED="2009-06-13 04:21:59 +0100" MODIFIED_BY="[Empty name]" NAME="Hong 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-06-13 04:21:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong W, Yuyuan L, Yuqiang L, Weihong S, Shoujun D</AU>
<TI>Treatment for nocturnal acid breakthrough</TI>
<SO>New Chinese Medicine</SO>
<YR>2002</YR>
<VL>33</VL>
<NO>9</NO>
<PG>539-541</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janiak--2007" MODIFIED="2009-07-22 13:41:13 +0100" MODIFIED_BY="Cathy Bennett" NAME="Janiak  2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 13:41:13 +0100" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janiak P, Thumshirn M, Menne D, Fox M, Halim S, Fried M at al</AU>
<TI>Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis-a randomized controlled, cross-over trial</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>9</NO>
<PG>1259-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jun-2005" MODIFIED="2009-06-13 04:55:09 +0100" MODIFIED_BY="[Empty name]" NAME="Jun 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-13 04:55:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jun S, Xiaoping X, Hanhua X, Xiaohua H</AU>
<TI>A Controlled Study of Famotidine and omeprazole on daytime and nocturnal gastric acid breakthrough in duodenal ulcer</TI>
<SO>Chinese Journal of Clinical Gastroenterology</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>5</NO>
<PG>212-213</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khoury-1999" MODIFIED="2009-07-22 13:39:34 +0100" MODIFIED_BY="Cathy Bennett" NAME="Khoury 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-07-22 13:39:34 +0100" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khoury RM, Katz PO, Hammod R, Castell DO</AU>
<TI>Bedtime ranitidine does not eliminate the need for a second daily does of omeprazole to suppress nocturnal gastric pH</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1999</YR>
<VL>13</VL>
<NO>5</NO>
<PG>675-678</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peghini-1998b" NAME="Peghini 1998b" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peghini PL, Katz PO, Castell DO</AU>
<TI>Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects</TI>
<SO>Gastroenterology</SO>
<YR>1998</YR>
<VL>115</VL>
<NO>6</NO>
<PG>1335-1339</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-07-22 14:17:15 +0100" MODIFIED_BY="Cathy Bennett">
<STUDY DATA_SOURCE="PUB" ID="STD-Brummer-1996" NAME="Brummer 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brummer RJM, Stockbrugger RW</AU>
<TI>Effect of nizatidine 300mg at night and omeprazole 20mg in the morning on 24-hour intragastric pH bacterial overgrowth in patients with acute duodenal ulcer</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>10</NO>
<PG>2048-2054</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chunli-2005" MODIFIED="2009-06-13 03:54:31 +0100" MODIFIED_BY="[Empty name]" NAME="Chunli 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-13 03:54:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chunli H, You J, Zhaohui W, Chunmeng J</AU>
<TI>Rabeprazole and Omeprazole treat for duonenal ulcers</TI>
<SO>Journal of Postgraduate Medicine</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>3</NO>
<PG>31-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fackler--2002" NAME="Fackler  2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fackler WK, Ours TM, Vaczi MF, Richter JE</AU>
<TI>Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>3</NO>
<PG>625-632</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fackler-2000" MODIFIED="2009-02-09 12:36:42 +0000" MODIFIED_BY="Cathy Bennett" NAME="Fackler 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-09 12:36:42 +0000" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fackler WK, Vaezi MF, Ours TM, Richter JE</AU>
<TI>Nocturnal acid breakthrough and H2RAs: Another viewpoint</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>9</NO>
<PG>2419</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-JianQiang-2005" MODIFIED="2009-06-13 04:48:14 +0100" MODIFIED_BY="[Empty name]" NAME="JianQiang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-13 04:48:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>JianQiang G, Shutian Z, Bin L, Qingling G, Weihua X, Hua L, Hongbo W</AU>
<TI>Comparision of inhibitive effect on gastric acid between single dose rabeprazole and esomeprazole in healthy volunteers</TI>
<SO>Chinese Journal of Clinical Pharmacy</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Judmaier-1994" NAME="Judmaier 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Judmaier G, Koelz HR</AU>
<TI>Comparision of pantoprazole and ranitidine in the treatment of acute duodenal ulcer</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>1</NO>
<PG>81-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Katsube-2000" MODIFIED="2009-07-22 14:14:41 +0100" MODIFIED_BY="Cathy Bennett" NAME="Katsube 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-22 14:14:41 +0100" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Katsube T, Adachi K, Kawamura A, Amano K, Uchida Y, Watanabe M, et al</AU>
<TI>Helicobacter pylori infection influences nocturnal gastric acid breakthrough</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>8</NO>
<PG>1049-1056</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keshang-2005" MODIFIED="2009-06-13 05:06:28 +0100" MODIFIED_BY="[Empty name]" NAME="Keshang 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-13 05:06:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keshang L, Wenhu C, Guanghuan C</AU>
<TI>Treatment for nocturnal heartburn of PPI ineffective nonerosive reflux disease</TI>
<SO>Journal of Postgraduate Medicine</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>6</NO>
<PG>25-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfefferkorn-2006" MODIFIED="2009-07-22 14:17:15 +0100" MODIFIED_BY="Cathy Bennett" NAME="Pfefferkorn 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 14:16:53 +0100" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pfefferkorn M, Croffie J, Gupta S, Molleston J, Eckert G, Corkins M, Fitzgerald J</AU>
<TI>Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors</TI>
<SO>Journal of Pediatric Gastroenterology &amp; Nutrition</SO>
<YR>2006</YR>
<VL>42</VL>
<NO>2</NO>
<PG>160-165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-2002" NAME="Robinson 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson M, Rodriguez-Stanley S, Ciociola AA, Filinto J, Zubaidi S, Miner PB, et al</AU>
<TI>Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole</TI>
<SO>Digestive Disease &amp; Sciences</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>2</NO>
<PG>265-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shimatani-2006" MODIFIED="2009-07-22 14:15:05 +0100" MODIFIED_BY="Cathy Bennett" NAME="Shimatani 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-07-22 14:15:05 +0100" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shimatani T, Inoue M, Kuroiwa T, Xu J, Nakamura M,Tazuma S, et al</AU>
<TI>Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine</TI>
<SO>Digestive Diseases &amp; Sciences.</SO>
<YR>2006</YR>
<VL>51</VL>
<NO>1</NO>
<PG>114-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shuwen--2000" NAME="Shuwen  2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shuwen X, Philip O, Katz JA, Castell DO</AU>
<TI>Bedtime H2 blockers control nocturnal gastric acid breakthrough in GERD patients</TI>
<SO>Gastroenterology</SO>
<YR>2000</YR>
<VL>118</VL>
<NO>4</NO>
<PG>A22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sugimoto-2005" MODIFIED="2009-06-13 06:41:54 +0100" MODIFIED_BY="[Empty name]" NAME="Sugimoto 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-13 06:41:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sugimoto M, Furuta T, Shirai N, Nakamura A , Kajimura M, Hishida A et al</AU>
<TI>Comparision of an increased dosage regimen rabeprazole versus a concomitent dosage regimen of Famotidine with rebeprazole for nocturnal acid inhibition in relation to cytochrome P4502C19 genotypes</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>2005</YR>
<VL>77</VL>
<NO>4</NO>
<PG>302-311</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tina-2003" MODIFIED="2009-02-09 12:37:19 +0000" MODIFIED_BY="Cathy Bennett" NAME="Tina 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-02-09 12:37:19 +0000" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tina M, Ours RN, Fackler WK, Richter JE, Vaezi MF</AU>
<TI>Nocturnal acid breakthrough: clinical significance and correlation with oesophageal acid exposure</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>3</NO>
<PG>545-550</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tutuian-2002" MODIFIED="2009-02-09 12:41:06 +0000" MODIFIED_BY="Cathy Bennett" NAME="Tutuian 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-02-09 12:41:06 +0000" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tutuian R, Katz PO, Ahmed F, Korn S, Castell DO</AU>
<TI>Over-the-counter H2-receptor antagonist do not compromise intragastric PH control with proton pump inhibitors</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>3</NO>
<PG>473-477</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Zyl-2000" NAME="Van Zyl 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Zyl JH, De K Grundling H, Van Rensburg CJ, Retief FJ, O'Keefe SJ, Theron I, et al</AU>
<TI>Efficacy and tolerability of 20mg pantoprazole versus 300mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind,parallel,and multicentre study</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology.</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>2</NO>
<PG>197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warrington-2007" MODIFIED="2009-07-22 14:15:39 +0100" MODIFIED_BY="Cathy Bennett" NAME="Warrington 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-22 14:15:39 +0100" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warrington S, Baisley K, Lee D, Lomax K, Delemos B, Boyce M, Morocutti A</AU>
<TI>Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn</TI>
<SO>Alimentary Pharmacology and Therapeutics.</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>4</NO>
<PG>511-517</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiaohui-2005" MODIFIED="2009-06-13 05:09:57 +0100" MODIFIED_BY="[Empty name]" NAME="Xiaohui 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-13 05:09:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiaohui L</AU>
<TI>Omeprazole combine ranitidine control for nocturnal gastric acid</TI>
<SO>Journal of Practical Training of Medicine</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>2</NO>
<PG>102-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xue-2001" MODIFIED="2009-02-09 12:41:17 +0000" MODIFIED_BY="Cathy Bennett" NAME="Xue 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-02-09 12:41:17 +0000" MODIFIED_BY="Cathy Bennett" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO</AU>
<TI>Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>9</NO>
<PG>1351-1356</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-06-13 06:41:54 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-08-04 13:41:15 +0100" MODIFIED_BY="Cathy Bennett">
<ADDITIONAL_REFERENCES MODIFIED="2009-08-04 13:41:15 +0100" MODIFIED_BY="Cathy Bennett">
<REFERENCE ID="REF-Bate-1990" MODIFIED="2009-07-22 14:17:50 +0100" MODIFIED_BY="Cathy Bennett" NAME="Bate 1990" TYPE="JOURNAL_ARTICLE">
<AU>Bate CM, Keeling PW, O'Morain C, Wilkinson SP, Foster DN, Mountford RA, et al</AU>
<TI>Comparison of omeprazole and cimetidine in reflux esophagitis: symptomatic, endoscopic, and histologic evaluations</TI>
<SO>Gut</SO>
<YR>1990</YR>
<VL>31</VL>
<NO>9</NO>
<PG>968-972</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bell-1992" MODIFIED="2009-07-28 10:18:59 +0100" MODIFIED_BY="[Empty name]" NAME="Bell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Bell NJ, Burget D, Howden CW, WilkinsonJ, Hunt RH</AU>
<TI>Appropriate acidsuppression for the management of gastro-oesophageal reflux disease</TI>
<SO>Digestion</SO>
<YR>1992</YR>
<VL>51</VL>
<NO>Suppl. 1</NO>
<PG>59-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-06-14 15:11:12 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzgerald-1996" MODIFIED="2009-02-09 12:33:42 +0000" MODIFIED_BY="Cathy Bennett" NAME="Fitzgerald 1996" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald RC, Omary MB, Triadafilopoulos G</AU>
<TI>Dynamic effects of acid on Barrett's oesophagus: an ex vivo proliferation and differentiation model</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1996</YR>
<VL>98</VL>
<NO>9</NO>
<PG>2120-2128</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furuta-2001" MODIFIED="2009-02-09 12:34:03 +0000" MODIFIED_BY="Cathy Bennett" NAME="Furuta 2001" TYPE="JOURNAL_ARTICLE">
<AU>Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T</AU>
<TI>Effect of high-dose lansoprazole on intragastric PH in subjects who are homozygous extensive metabolizers of cytochrome P450C19</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2001</YR>
<VL>70</VL>
<NO>5</NO>
<PG>484-492</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-06-24 13:29:27 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins, JPT,Green, S. (Eds.)</AU>
<SO>Designing search strategies. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0</SO>
<YR>10 April 2008</YR>
<VL>Section 6.4</VL>
<EN>updated 2008</EN>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hongo-1992" MODIFIED="2009-02-09 12:35:19 +0000" MODIFIED_BY="Cathy Bennett" NAME="Hongo 1992" TYPE="JOURNAL_ARTICLE">
<AU>Hongo M, Ohara S, Hirasawa Y, Abe S, Asaki S, Toyota T</AU>
<TI>Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>1992</YR>
<VL>37</VL>
<NO>6</NO>
<PG>882-890</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Katz-1998" MODIFIED="2009-02-09 12:35:28 +0000" MODIFIED_BY="Cathy Bennett" NAME="Katz 1998" TYPE="JOURNAL_ARTICLE">
<AU>Katz PO, Anderson C, Khoury R, Castell DO</AU>
<TI>Gastric-esophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>12</NO>
<PG>1231-1234</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2009-07-28 10:19:38 +0100" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-989</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maton-1991" MODIFIED="2009-02-09 12:35:37 +0000" MODIFIED_BY="Cathy Bennett" NAME="Maton 1991" TYPE="JOURNAL_ARTICLE">
<AU>Maton PN</AU>
<TI>Omeprazole</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>324</VL>
<NO>14</NO>
<PG>965-975</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2009-08-04 13:41:15 +0100" MODIFIED_BY="Cathy Bennett" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-613</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ouatu_x002d_Lascar-1999" MODIFIED="2008-10-30 10:11:03 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Ouatu-Lascar 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ouatu-Lascar R, Fitzgerald R, Triadafilopoulos G</AU>
<TI>Differentiation and proliferation in Barrett's oesophagus and the effects of acid suppression</TI>
<SO>Gastroenterology</SO>
<YR>1999</YR>
<VL>117</VL>
<NO>2</NO>
<PG>327-335</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peghini-1998a" MODIFIED="2009-02-09 12:35:57 +0000" MODIFIED_BY="Cathy Bennett" NAME="Peghini 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Peghini PL, Katz PO, Bracy NA, Castell DA</AU>
<TI>Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1998</YR>
<VL>93</VL>
<NO>5</NO>
<PG>763-767</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peters-1999" MODIFIED="2008-10-30 10:11:03 +0000" MODIFIED_BY="Karen Hovhannisyan" NAME="Peters 1999" TYPE="JOURNAL_ARTICLE">
<AU>Peters FTM, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB</AU>
<TI>Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study</TI>
<SO>Gut</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>4</NO>
<PG>489-494</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2009-06-14 14:24:24 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF., Chalmers I., Hayes R., Altman D</AU>
<TI>Empirical evidence of bias</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shirai-2002" MODIFIED="2009-02-09 12:33:09 +0000" MODIFIED_BY="Cathy Bennett" NAME="Shirai 2002" TYPE="JOURNAL_ARTICLE">
<AU>Shirai N, Furuta T, Xiao F, Kajimura M, Hanai H, Ohashi K, et al</AU>
<TI>Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime night-time in different CYP2C19 genotype groups</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>4</NO>
<PG>837-846</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Herwaarden-2000" MODIFIED="2009-02-09 12:36:13 +0000" MODIFIED_BY="Cathy Bennett" NAME="Van Herwaarden 2000" TYPE="JOURNAL_ARTICLE">
<AU>Van Herwaarden MA, Samson M, Smout AJ</AU>
<TI>Helicobacter pylori eradication increases nocturnal acid breakthrough</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>7</NO>
<PG>961-962</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-08-04 11:24:19 +0100" MODIFIED_BY="Cathy Bennett">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-08-04 11:24:19 +0100" MODIFIED_BY="Cathy Bennett" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-08-04 11:23:38 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Bing-2005">
<CHAR_METHODS MODIFIED="2009-08-04 11:23:38 +0100" MODIFIED_BY="Cathy Bennett">
<P>Randomised clinical trial</P>
<P>Generation of allocation sequence: unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: not performed blind trial.</P>
<P>Follow up: unclear</P>
<P>Sample size: estimation reported or not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-22 13:43:57 +0100" MODIFIED_BY="Cathy Bennett">
<P>30 participants in total: GERD participants, mean age of 35 years.</P>
<P>Intervention group:15 cases, Control group:15 cases.</P>
<P>Excluded criteria: Used acid suppression drugs in 4 weeks</P>
<P>
<I>Helicobacter pylori</I> status: all negative</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-20 12:01:29 +0100" MODIFIED_BY="Cathy Bennett">
<P>Intervention group: 20mg omeprazole before breakfast and before dinner with 40mg famotidine at bedtime for 7 days;<BR/>Control group: 20mg omeprazole before breakfast and before dinner for 7 days;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-22 13:39:08 +0100" MODIFIED_BY="Cathy Bennett">
<P>1. The prevalence rate of nocturnal gastric acid breakthrough.<BR/>2. Percentage of time which pH is less than 4.0 inside the stomach.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-13 03:45:49 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of H2RAs: &lt;4 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-22 14:27:05 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Cong-2004">
<CHAR_METHODS MODIFIED="2009-07-22 14:27:05 +0100" MODIFIED_BY="Cathy Bennett">
<P>Randomised clinical trial</P>
<P>Generation of allocation sequence: unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: not performed as a blind trial.</P>
<P>Follow up: unclear.</P>
<P>Sample size: estimation reported or not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-22 14:26:43 +0100" MODIFIED_BY="Cathy Bennett">
<P>40 participants in total: duodenal ulcer participants, mean age of 56.2 years.</P>
<P>Intervention group 1:10 cases, Control group 1:10 cases.Intervention group 2:10 cases, Control group 2:10 cases.</P>
<P>Excluded criteria: None.</P>
<P>
<I>Helicobacter pylori</I> status: all positive</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-20 12:01:25 +0100" MODIFIED_BY="Cathy Bennett">
<P>Intervention group 1:20mg omeprazole before breakfast and before dinner with 20mg famotidine at bedtime for 5 days;<BR/>Control group 1: 20mg omeprazole before breakfast and before dinner for 5 days;</P>
<P>Intervention group 2:20mg omeprazole before breakfast with 20mg famotidine at bedtime for 5 days;<BR/>Control group 2: 20mg omeprazole before breakfast for 5 days;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-22 13:39:10 +0100" MODIFIED_BY="Cathy Bennett">
<P>1. The prevalence rate of nocturnal gastric acid breakthrough.</P>
<P>2. Percentage of time which pH is less than 4.0 inside the stomach.</P>
<P>3. Median intragastric pH.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-13 04:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of H2RAs: &lt;4 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 11:23:47 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Cong-2004b">
<CHAR_METHODS MODIFIED="2009-08-04 11:23:47 +0100" MODIFIED_BY="Cathy Bennett">
<P>Randomised clinical trial</P>
<P>Generation of allocation sequence: unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: not performed blind trial.</P>
<P>Follow up: Unclear.</P>
<P>Sample size: estimation reported or not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-22 14:27:23 +0100" MODIFIED_BY="Cathy Bennett">
<P>32 participants in total: duodenal ulcer participants, mean age of 66.1 years.</P>
<P>Intervention group 1:10 cases, Control group 1: 10 cases. Intervention group 2: 10 cases, Control group 2: 10 cases.</P>
<P>Excluded criteria: None.</P>
<P>
<I>Helicobacter pylori</I> status: all positive</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-22 13:56:59 +0100" MODIFIED_BY="Cathy Bennett">
<P>Intervention group 1:20mg omeprazole before breakfast and before dinner with 20mg famotidine at bedtime for 5 days;<BR/>Control group 1: 20mg omeprazole before breakfast and before dinner for 5 days;</P>
<P>Intervention group 2: 20mg omeprazole before breakfast with 20mg famotidine at bedtime for 5 days;<BR/>Control group 2: 20mg omeprazole before breakfast for 5 days;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-22 13:39:11 +0100" MODIFIED_BY="Cathy Bennett">
<P>1. The prevalence rate of nocturnal gastric acid breakthrough.<BR/>2. Percentage of time which pH is less than 4.0 inside the stomach.</P>
<P>3. Median intragastric pH.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-13 04:19:15 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of H2RAs: &lt;4 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-07-22 14:27:32 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Hong-2002">
<CHAR_METHODS MODIFIED="2009-07-20 12:00:10 +0100" MODIFIED_BY="Cathy Bennett">
<P>Randomised clinical trial<BR/>Generation of allocation sequence: sortition.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: not performed blind trial.</P>
<P>Follow up: Unclear.</P>
<P>Sample size: estimate reported or not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-22 14:27:32 +0100" MODIFIED_BY="Cathy Bennett">
<P>44 participants in total: duodenal ulcer participants, mean age of 45 years.</P>
<P>Intervention group 1: 11 cases, Control group 1: 11 cases. Intervention group 2:11 cases, Control group 2:11 cases.</P>
<P>Excluded criteria: None.</P>
<P>
<I>Helicobacter pylori</I> status: 36 positive</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-20 12:00:51 +0100" MODIFIED_BY="Cathy Bennett">
<P>Intervention group1: 20mg omeprazole before breakfast with 150mg ranitidine at bedtime for 5 days;<BR/>Control group1: 20mg omeprazole before breakfast for 5 days;</P>
<P>Intervention group 2: 20mg omeprazole before breakfast and before dinner with 150mg ranitidine at bedtime for 5 days;<BR/>Control group 2: 20mg omeprazole before breakfast and before dinner for 5 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-20 12:00:48 +0100" MODIFIED_BY="Cathy Bennett">
<OL>
<LI>The prevalence rate of nocturnal gastric acid breakthrough.</LI>
<LI>Percentage of time which pH is less than 4.0 inside the stomach.</LI>
<LI>Median intragastric pH.</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-13 04:59:31 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of H2RAs: &lt;4 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 11:23:56 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Janiak--2007">
<CHAR_METHODS MODIFIED="2009-08-04 11:23:56 +0100" MODIFIED_BY="Cathy Bennett">
<P>Randomised clinical trial, cross-over design.</P>
<P>Generation of allocation sequence: unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: yes (double-blind)</P>
<P>Follow up: Inadequate.</P>
<P>Sample size: estimation reported or not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-22 13:44:17 +0100" MODIFIED_BY="Cathy Bennett">
<P>14 participants in total: participants with systemic sclerosis and GERD symptoms, mean age of 61.7 years.</P>
<P>Excluded criteria: pregnancy or lactation, alcohol or drug abuse, severe concomitant organic or psychiatric disease and previous oesophageal or gastric surgery. Acid suppression therapy with H2-receptor antagonists was discontinued for at least 2 weeks prior to the study.</P>
<P>
<I>Helicobacter pylori</I> status:1 positive</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-22 13:46:39 +0100" MODIFIED_BY="Cathy Bennett">
<P>Participants were treated with omeprazole 20 mg b.d. and either placebo or ranitidine 300 mg at bedtime for 6 weeks in a randomized, cross-over, placebo controlled study. At the end of each period a 24h pH-study with intragastric and oesophageal pH measurement was performed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-22 13:39:12 +0100" MODIFIED_BY="Cathy Bennett">
<P>1. The prevalence rate of nocturnal gastric acid breakthrough.<BR/>2. Median intragastric pH.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-13 09:22:41 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of H2RAs: &gt;4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 11:24:05 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Jun-2005">
<CHAR_METHODS MODIFIED="2009-08-04 11:24:05 +0100" MODIFIED_BY="Cathy Bennett">
<P>Randomised clinical trial</P>
<P>Generation of allocation sequence: unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: not performed blind trial.</P>
<P>Follow up: unclear.</P>
<P>Sample size: estimation reported or not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-22 14:27:55 +0100" MODIFIED_BY="Cathy Bennett">
<P>20 participants in total: duodenal ulcer participants, mean age of 38.6 years.</P>
<P>Intervention group: 10 cases, Control group:10 cases.</P>
<P>Excluded criteria: None.</P>
<P>
<I>Helicobacter pylori</I> status: all negative</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-22 12:22:56 +0100" MODIFIED_BY="Cathy Bennett">
<P>Intervention group: 20mg omeprazole before breakfast with 40mg famotidine at bedtime for 7 days;<BR/>Control group: 20mg omeprazole before breakfast and before dinner for 7 days;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-22 13:39:12 +0100" MODIFIED_BY="Cathy Bennett">
<P>1. The prevalence rate of nocturnal gastric acid breakthrough.<BR/>2. Percentage of time which pH is less than 4.0 inside the stomach.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-06-13 04:59:59 +0100" MODIFIED_BY="[Empty name]">
<P>Duration of H2RAs: &lt;4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 11:24:12 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Khoury-1999">
<CHAR_METHODS MODIFIED="2009-08-04 11:24:12 +0100" MODIFIED_BY="Cathy Bennett">
<P>Randomised clinical trial, cross-over design</P>
<P>Generation of allocation sequence: unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: yes (double-blind).</P>
<P>Follow up: unclear.</P>
<P>Sample size: estimation reported or not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-22 12:00:19 +0100" MODIFIED_BY="Cathy Bennett">
<P>20 participants in total: healthy asymptomatic volunteers, mean age of 32.7 years.<BR/>Excluded criteria: None.<BR/>
<I>Helicobacter pylori</I> status was assessed by serology:15 negative and 5 positive.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment with 20mg omeprazole before breakfast and before dinner with placebo at bedtime for 7 days or 20mg omeprazole before breakfast, placebo before dinner and 150 mg ranitidine at bedtime for 7 days. The length of treatment was 7 day. The washout time was 1 week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-22 13:38:54 +0100" MODIFIED_BY="Cathy Bennett">
<P>1. The prevalence rate of nocturnal gastric acid breakthrough.<BR/>2. Percentage of time which pH is less than 4.0 inside the stomach in the upright position.<BR/>3. Percentage of time which pH is less than 4.0 inside the stomach in recumbent position.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Duration of H2RAs: &lt;4 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-04 11:24:19 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Peghini-1998b">
<CHAR_METHODS MODIFIED="2009-08-04 11:24:19 +0100" MODIFIED_BY="Cathy Bennett">
<P>Randomised clinical trial, cross-over design</P>
<P>Generation of allocation sequence: unclear.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: yes (double-blind).</P>
<P>Follow up: unclear.</P>
<P>Sample size: estimation reported or not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-07-22 12:00:19 +0100" MODIFIED_BY="Cathy Bennett">
<P>12 participants in total: healthy asymptomatic volunteers, mean age of 31 years.<BR/>Excluded criteria: None.<BR/>Immunoglobulin (Ig) G antibodies to <I>Helicobacter pylori</I>: all negative serological results.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Pre-treatment with 20 mg oral omeprazole twice daily 15-30 minutes before breakfast and dinner for 7 days. Beginning on day 8, additional treatments with placebo, 150mg ranitidine, 300mg ranitidine and an additional 20mg dose of omeprazole were given at bedtime. The length of treatment was only 1 day. The author did not mention washout time but mentioned that all 4 studies were completed over 4 to 21 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-07-22 13:38:57 +0100" MODIFIED_BY="Cathy Bennett">
<P>1. The prevalence rate of nocturnal gastric acid breakthrough.<BR/>2. Median intragastric pH.<BR/>3. Percentage of time which pH is less than 4.0 inside the stomach.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Duration of H2RAs: &lt;4 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-07-22 14:29:41 +0100" MODIFIED_BY="Cathy Bennett" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-07-22 13:39:00 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Brummer-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 13:39:00 +0100" MODIFIED_BY="Cathy Bennett">
<P>The aim of this study was to compare the effect of intragastric pH control of daytime omeprazole and lonely night-time nizatidine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-13 03:54:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chunli-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-13 03:54:49 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fackler--2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 14:09:28 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Fackler-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 14:09:28 +0100" MODIFIED_BY="Cathy Bennett">
<P>Non-randomized controlled trial, abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-06-13 04:49:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-JianQiang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-06-13 04:49:53 +0100" MODIFIED_BY="[Empty name]">
<P>The aim of this study was to compare the efficacy of rabeprazole and esomeprazole.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Judmaier-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>The aim of this study was to compare the efficacy of daytime pantoprazole and lonely nightime ranitidine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Katsube-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 14:09:37 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Keshang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 14:09:37 +0100" MODIFIED_BY="Cathy Bennett">
<P>The intervention group is famotidine plus other drugs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 14:28:54 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Pfefferkorn-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 14:28:54 +0100" MODIFIED_BY="Cathy Bennett">
<P>The participants were children, the regimen of the intervention was different from our protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robinson-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 14:28:45 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Shimatani-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 14:28:45 +0100" MODIFIED_BY="Cathy Bennett">
<P>The aim of this study was to compare the efficacy of lafutidine and famotidine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shuwen--2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 14:29:32 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Sugimoto-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 14:29:32 +0100" MODIFIED_BY="Cathy Bennett">
<P>The aim of the study was to assess the different genotype react to drugs, none of the outcomes we specified were reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tina-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomized controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 13:39:00 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Tutuian-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 13:39:00 +0100" MODIFIED_BY="Cathy Bennett">
<P>The aim of this study was to assess daytime intragastric pH control of proton pump inhibitors on the day after night-time or early morning H2RAs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 14:10:03 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Van-Zyl-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 14:10:03 +0100" MODIFIED_BY="Cathy Bennett">
<P>The aim of this study was to compare the efficacy and tolerability of daytime pantoprazole and night-time ranitidine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 13:45:59 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Warrington-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 13:45:59 +0100" MODIFIED_BY="Cathy Bennett">
<P>The aim of this study was to compare the efficacy of rabeprazole 20 mg and pantoprazole 40 mg in participants with GERD and nocturnal heartburn.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 14:29:41 +0100" MODIFIED_BY="Cathy Bennett" STUDY_ID="STD-Xiaohui-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 14:29:41 +0100" MODIFIED_BY="Cathy Bennett">
<P>The aim of the study was to assess the healing rate of RE, none of the outcomes we specified were reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xue-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-06-13 06:41:54 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-07-22 13:44:41 +0100" MODIFIED_BY="Cathy Bennett" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-16 14:57:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bing-2005">
<DESCRIPTION>
<P>Quote:"patients were randomly allocated." The method of sequence generation was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:06:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cong-2004">
<DESCRIPTION>
<P>Quote:"patients were randomly allocated." The method of sequence generation was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:16:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cong-2004b">
<DESCRIPTION>
<P>Quote:"patients were randomly allocated." The method of sequence generation was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>Quote:"patients were randomly allocated and the allocation sequences were generated by sortition"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:23:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Janiak--2007">
<DESCRIPTION>
<P>Quote:"patients were randomly allocated." The method of sequence generation was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:28:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jun-2005">
<DESCRIPTION>
<P>Quote:"patients were randomly allocated." The method of sequence generation was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-22 13:44:41 +0100" MODIFIED_BY="Cathy Bennett" RESULT="UNKNOWN" STUDY_ID="STD-Khoury-1999">
<DESCRIPTION>
<P>Quote:"patients were randomly allocated." The method of sequence generation was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:33:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peghini-1998b">
<DESCRIPTION>
<P>Quote:"patients were randomly allocated." The method of sequence generation was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-07-19 14:34:03 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 10:17:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bing-2005">
<DESCRIPTION>
<P>The method of allocation concealment was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:06:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cong-2004">
<DESCRIPTION>
<P>The method of allocation concealment was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:16:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cong-2004b">
<DESCRIPTION>
<P>The method of allocation concealment was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:20:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>The method of allocation concealment was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:23:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Janiak--2007">
<DESCRIPTION>
<P>The method of allocation concealment was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:28:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jun-2005">
<DESCRIPTION>
<P>The method of allocation concealment was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:32:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khoury-1999">
<DESCRIPTION>
<P>The method of allocation concealment was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:34:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peghini-1998b">
<DESCRIPTION>
<P>The method of allocation concealment was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-07-22 14:28:35 +0100" MODIFIED_BY="Cathy Bennett" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-20 11:57:08 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Bing-2005">
<DESCRIPTION>
<P>Not performed as a blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-20 11:58:25 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Cong-2004">
<DESCRIPTION>
<P>Not performed as a blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-20 11:59:21 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Cong-2004b">
<DESCRIPTION>
<P>Not performed as a blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-20 12:01:54 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>Not performed as a blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-19 14:25:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Janiak--2007">
<DESCRIPTION>
<P>Quote:"double-blind,cross-over, placebo controlled study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-22 12:23:01 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Jun-2005">
<DESCRIPTION>
<P>Not performed as a blind trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-19 14:32:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khoury-1999">
<DESCRIPTION>
<P>Quote:"double-blind,cross-over, placebo controlled study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-07-22 14:28:35 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Peghini-1998b">
<DESCRIPTION>
<P>Quote:"double-blind, cross-over, placebo controlled study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-07-22 14:09:16 +0100" MODIFIED_BY="Cathy Bennett" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-22 13:44:01 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Bing-2005">
<DESCRIPTION>
<P>No participants missing from the 2 groups, but the study used the median to report percentage of time which pH was less than 4.0 inside the stomach, so we cannot extract data for meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-22 13:44:06 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Cong-2004">
<DESCRIPTION>
<P>No participants missing from the 4 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-22 13:44:11 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Cong-2004b">
<DESCRIPTION>
<P>No participants missing from the 4 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-22 13:44:15 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>No participants missing from the 4 groups, but the study used the median to report percentage of time which pH was less than 4.0 inside the stomach, so we cannot extract data for meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-22 13:44:25 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Janiak--2007">
<DESCRIPTION>
<P>4 participants missing from the study, the reason was not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-22 13:44:29 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Jun-2005">
<DESCRIPTION>
<P>No participants missing from the 4 groups, but the study used the median to report percentage of time which pH is less than 4.0 inside the stomach, so we cannot extract data for meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-22 13:42:06 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Khoury-1999">
<DESCRIPTION>
<P>No patients missing from the 4 groups,but the study used the median to report percentage of time which pH is less than 4.0 inside the stomach, so we cannot extract data for meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-07-22 14:09:16 +0100" MODIFIED_BY="Cathy Bennett" RESULT="YES" STUDY_ID="STD-Peghini-1998b">
<DESCRIPTION>
<P>No participants missing from the 4 groups, but the study used the median to report percentage of time which pH is less than 4.0 inside the stomach and median intragastric pH, so we cannot extract data for meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Bing-2005">
<DESCRIPTION>
<P>All outcomes were reported, but the study did not measured the long-term effects of H2RAs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Cong-2004">
<DESCRIPTION>
<P>All outcomes programed have been reported, but the study did not measure the long-term effects of H2RAs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Cong-2004b">
<DESCRIPTION>
<P>All outcomes programed have been reported, but the study did not measure the long-term effects of H2RAs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>All outcomes programed have been reported, but the study did not measure the long-term effects of H2RAs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-19 14:27:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Janiak--2007">
<DESCRIPTION>
<P>All outcomes programed have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Jun-2005">
<DESCRIPTION>
<P>All outcomes programed have been reported, but the study not measured the long-term effects of H2RAs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Khoury-1999">
<DESCRIPTION>
<P>All outcomes were reported, but the study did not measure the long-term effects of H2RAs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-04 11:15:29 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Peghini-1998b">
<DESCRIPTION>
<P>All outcomes programed were reported, but the study did not measure the long-term effects of H2RAs.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-07-22 13:47:57 +0100" MODIFIED_BY="Cathy Bennett" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-20 11:57:54 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Bing-2005">
<DESCRIPTION>
<P>The study had no exclusion criteria and did not report adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-20 11:58:42 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Cong-2004">
<DESCRIPTION>
<P>The study had no exclusion criteria and did not report adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-20 11:59:39 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Cong-2004b">
<DESCRIPTION>
<P>The study had no exclusion criteria and did not report adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-20 12:02:27 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Hong-2002">
<DESCRIPTION>
<P>The study had no exclusion criteria and did not report adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-22 13:47:57 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Janiak--2007">
<DESCRIPTION>
<P>The study did not report adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-22 13:47:53 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Jun-2005">
<DESCRIPTION>
<P>The study had no exclusion criteria and did not report adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-22 13:47:44 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Khoury-1999">
<DESCRIPTION>
<P>The study did not report adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-22 13:47:35 +0100" MODIFIED_BY="Cathy Bennett" RESULT="NO" STUDY_ID="STD-Peghini-1998b">
<DESCRIPTION>
<P>The study did not report adverse events.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-07-22 13:51:03 +0100" MODIFIED_BY="Cathy Bennett">
<COMPARISON ID="CMP-001" MODIFIED="2009-07-22 13:51:03 +0100" MODIFIED_BY="Cathy Bennett" NO="1">
<NAME>H2RAs vs control</NAME>
<DICH_OUTCOME CHI2="22.97790399997395" CI_END="0.7462836137858541" CI_START="0.3048092307761072" CI_STUDY="95" CI_TOTAL="95" DF="11.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.47694248527351774" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="82" I2="52.12792254675418" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.12709609411658776" LOG_CI_START="-0.5159718850541415" LOG_EFFECT_SIZE="-0.3215339895853646" METHOD="MH" MODIFIED="2009-06-18 08:33:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.017802408257663438" P_Q="0.0" P_Z="0.0011906430188419839" Q="0.0" RANDOM="YES" SCALE="902.43" SORT_BY="EFFECT_SIZE" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2595230109899816" TOTALS="YES" TOTAL_1="137" TOTAL_2="137" WEIGHT="100.0" Z="3.2411122218404653">
<NAME>Prevalence rate of nocturnal gastric acid breakthrough</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="22.366549025464415" CI_END="0.7242969275396574" CI_START="0.2518432394893263" DF="10.0" EFFECT_SIZE="0.427093999704694" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="74" I2="55.29037587061394" ID="CMP-001.01.01" LOG_CI_END="-0.14008335706823746" LOG_CI_START="-0.5988697029038994" LOG_EFFECT_SIZE="-0.3694765299860684" MODIFIED="2009-06-18 08:33:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.013342369483967276" P_Z="0.0015948132730723727" STUDIES="7" TAU2="0.3512977561019687" TOTAL_1="127" TOTAL_2="127" WEIGHT="85.1421737107074" Z="3.156853722778067">
<NAME>Short-trem</NAME>
<DICH_DATA CI_END="1.1448362319904497" CI_START="0.024263538313669918" EFFECT_SIZE="0.16666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.058743365601929894" LOG_CI_START="-1.615045866369217" LOG_EFFECT_SIZE="-0.7781512503836436" MODIFIED="2009-06-13 14:46:45 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.983192080250175" STUDY_ID="STD-Cong-2004" TOTAL_1="10" TOTAL_2="10" VAR="0.9666666666666667" WEIGHT="4.2553899452057165"/>
<DICH_DATA CI_END="3.7419210762620905" CI_START="0.01068969633105066" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5730946232213574" LOG_CI_START="-1.9710346318933951" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2009-06-13 14:51:05 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="1.4944341180973262" STUDY_ID="STD-Hong-2002" TOTAL_1="11" TOTAL_2="11" VAR="2.233333333333333" WEIGHT="2.093147179177524"/>
<DICH_DATA CI_END="1.3510724380256207" CI_START="0.029606110578684966" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.13067863443390323" LOG_CI_START="-1.5286186431059408" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2009-06-13 14:48:05 +0100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.9746794344808963" STUDY_ID="STD-Cong-2004b" TOTAL_1="8" TOTAL_2="8" VAR="0.95" WEIGHT="4.314027246942853"/>
<DICH_DATA CI_END="0.7374451299674198" CI_START="0.10086196554385313" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.1322702880804878" LOG_CI_START="-0.9962725727966374" LOG_EFFECT_SIZE="-0.5642714304385626" MODIFIED="2009-06-13 15:16:29 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.5075192189225523" STUDY_ID="STD-Peghini-1998b" TOTAL_1="12" TOTAL_2="12" VAR="0.25757575757575757" WEIGHT="10.090751597974041"/>
<DICH_DATA CI_END="7.140168426766256" CI_START="0.015561413186640009" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8537084563073323" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-06-13 14:47:38 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Cong-2004b" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="1.9297256018108464"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.4771212547196625" MODIFIED="2009-06-13 14:46:09 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Cong-2004" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="1.9013151948005318"/>
<DICH_DATA CI_END="0.8240980382907817" CI_START="0.16045591521238406" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" LOG_CI_END="-0.08402111966696243" LOG_CI_START="-0.7946442679935628" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2009-06-13 15:07:28 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.41742355496836103" STUDY_ID="STD-Peghini-1998b" TOTAL_1="12" TOTAL_2="12" VAR="0.1742424242424243" WEIGHT="12.029347664410947"/>
<DICH_DATA CI_END="1.2005001082166866" CI_START="0.15299746175000142" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.07936220354165731" LOG_CI_START="-0.8153157741308461" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-06-13 14:53:12 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.5255382728122436" STUDY_ID="STD-Jun-2005" TOTAL_1="10" TOTAL_2="10" VAR="0.2761904761904762" WEIGHT="9.740122938994551"/>
<DICH_DATA CI_END="1.2412288516716943" CI_START="0.1479771189175812" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.09385186196222604" LOG_CI_START="-0.8298054325514149" LOG_EFFECT_SIZE="-0.36797678529459443" MODIFIED="2009-06-13 14:50:30 +0100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.5425608669746597" STUDY_ID="STD-Hong-2002" TOTAL_1="11" TOTAL_2="11" VAR="0.2943722943722943" WEIGHT="9.420399802454286"/>
<DICH_DATA CI_END="0.9896205217436878" CI_START="0.20877858301067687" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="-0.004531307328376936" LOG_CI_START="-0.6803140543160355" LOG_EFFECT_SIZE="-0.3424226808222063" MODIFIED="2009-06-13 14:39:49 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.3969581307590986" STUDY_ID="STD-Bing-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.1575757575757576" WEIGHT="12.510023089154101"/>
<DICH_DATA CI_END="1.937512282543382" CI_START="0.8064465005346437" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.2872444643261707" LOG_CI_START="-0.09342443831005781" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-06-13 15:33:36 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.22360679774997894" STUDY_ID="STD-Khoury-1999" TOTAL_1="20" TOTAL_2="20" VAR="0.04999999999999999" WEIGHT="16.857923449781993"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3576109393017348" CI_START="0.41433078042912114" DF="0.0" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.13277532876397893" LOG_CI_START="-0.3826528019805788" LOG_EFFECT_SIZE="-0.12493873660829993" MODIFIED="2009-06-18 08:30:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3420194833753809" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="14.857826289292596" Z="0.9501826129376018">
<NAME>Long-trem</NAME>
<DICH_DATA CI_END="1.3576109393017348" CI_START="0.41433078042912114" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.13277532876397893" LOG_CI_START="-0.3826528019805788" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="23" O_E="0.0" SE="0.3027650354097491" STUDY_ID="STD-Janiak--2007" TOTAL_1="10" TOTAL_2="10" VAR="0.09166666666666662" WEIGHT="14.857826289292596"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.973921898311858" CI_END="-8.29879958663415" CI_START="-12.5139552009685" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.406377393801325" ESTIMABLE="YES" I2="49.781733824679634" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2009-06-13 16:31:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.11288594668382046" P_Q="1.0" P_Z="3.757217706977351E-22" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="36" TOTAL_2="36" UNITS="" WEIGHT="100.0" Z="9.67751929823037">
<NAME>Percentage of time during which pH is less than 4.0 inside the stomach</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-7.779966796896866" CI_START="-18.360033203103136" EFFECT_SIZE="-13.07" ESTIMABLE="YES" MEAN_1="17.8" MEAN_2="30.87" MODIFIED="2009-06-13 16:31:52 +0100" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="6.09" SD_2="5.98" SE="2.69904612780145" STUDY_ID="STD-Cong-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="15.872686468794223"/>
<CONT_DATA CI_END="-3.8760482492100694" CI_START="-13.303951750789931" EFFECT_SIZE="-8.59" ESTIMABLE="YES" MEAN_1="7.73" MEAN_2="16.32" MODIFIED="2009-06-13 16:30:29 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="4.75" SD_2="5.94" SE="2.405121618546555" STUDY_ID="STD-Cong-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="19.989271536403592"/>
<CONT_DATA CI_END="-4.293502882087786" CI_START="-11.326497117912215" EFFECT_SIZE="-7.8100000000000005" ESTIMABLE="YES" MEAN_1="7.91" MEAN_2="15.72" MODIFIED="2009-06-13 16:25:29 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="3.11" SD_2="4.01" SE="1.794164150795573" STUDY_ID="STD-Cong-2004b" TOTAL_1="8" TOTAL_2="8" WEIGHT="35.920858030675625"/>
<CONT_DATA CI_END="-9.53241004555452" CI_START="-17.46758995444548" EFFECT_SIZE="-13.5" ESTIMABLE="YES" MEAN_1="16.47" MEAN_2="29.97" MODIFIED="2009-06-13 16:29:03 +0100" MODIFIED_BY="[Empty name]" ORDER="15" SD_1="3.27" SD_2="4.7" SE="2.0243177863171584" STUDY_ID="STD-Cong-2004b" TOTAL_1="8" TOTAL_2="8" WEIGHT="28.21718396412656"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="29.37172407761942" CI_END="1.6493314042588083" CI_START="0.7840919452777744" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.2167116747682913" ESTIMABLE="YES" I2="82.9768249668058" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2009-07-22 13:51:03 +0100" MODIFIED_BY="Cathy Bennett" NO="3" P_CHI2="1.960145416080028E-5" P_Q="1.0" P_Z="3.5426144149615633E-8" Q="0.0" RANDOM="YES" SCALE="6.84" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.23038030310197635" TOTALS="YES" TOTAL_1="58" TOTAL_2="58" UNITS="" WEIGHT="100.00000000000003" Z="5.512256837947876">
<NAME>Median intragastric pH</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>Experimental</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours experimental</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.8014227854741183" CI_START="0.6585772145258809" EFFECT_SIZE="1.2299999999999995" ESTIMABLE="YES" MEAN_1="5.38" MEAN_2="4.15" MODIFIED="2009-06-13 16:51:53 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="0.6" SD_2="0.7" SE="0.291547594742265" STUDY_ID="STD-Cong-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="15.448342681566109"/>
<CONT_DATA CI_END="1.8746044456756439" CI_START="1.1253955543243561" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="7.09" MEAN_2="5.59" MODIFIED="2009-06-13 16:50:24 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SD_1="0.38" SD_2="0.47" SE="0.191128229207514" STUDY_ID="STD-Cong-2004" TOTAL_1="10" TOTAL_2="10" WEIGHT="18.253708982804127"/>
<CONT_DATA CI_END="1.7685214773480542" CI_START="0.6114785226519449" EFFECT_SIZE="1.1899999999999995" ESTIMABLE="YES" MEAN_1="5.39" MEAN_2="4.2" MODIFIED="2009-06-13 16:55:58 +0100" MODIFIED_BY="[Empty name]" ORDER="23" SD_1="0.57" SD_2="0.61" SE="0.2951694428629088" STUDY_ID="STD-Cong-2004b" TOTAL_1="8" TOTAL_2="8" WEIGHT="15.344949988979224"/>
<CONT_DATA CI_END="1.9107530963337809" CI_START="1.4892469036662195" EFFECT_SIZE="1.7000000000000002" ESTIMABLE="YES" MEAN_1="7.11" MEAN_2="5.41" MODIFIED="2009-06-13 16:55:11 +0100" MODIFIED_BY="[Empty name]" ORDER="22" SD_1="0.22" SD_2="0.21" SE="0.10752906583803283" STUDY_ID="STD-Cong-2004b" TOTAL_1="8" TOTAL_2="8" WEIGHT="20.137416508652986"/>
<CONT_DATA CI_END="1.9909513763026623" CI_START="0.8090486236973365" EFFECT_SIZE="1.3999999999999995" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="4.7" MODIFIED="2009-06-13 16:53:01 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="0.6" SD_2="0.8" SE="0.30151134457776363" STUDY_ID="STD-Hong-2002" TOTAL_1="11" TOTAL_2="11" WEIGHT="15.16421982223195"/>
<CONT_DATA CI_END="0.6575024134002201" CI_START="-0.4575024134002208" EFFECT_SIZE="0.09999999999999964" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="6.2" MODIFIED="2009-06-13 16:53:38 +0100" MODIFIED_BY="[Empty name]" ORDER="21" SD_1="0.5" SD_2="0.8" SE="0.284445233584764" STUDY_ID="STD-Hong-2002" TOTAL_1="11" TOTAL_2="11" WEIGHT="15.651362015765624"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-07-22 13:51:04 +0100" MODIFIED_BY="Cathy Bennett">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-07-01 14:22:43 +0100" MODIFIED_BY="Cathy Bennett" NO="1" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 H2RAs vs control, outcome: 1.1 Prevalence rate of nocturnal gastric acid breakthrough.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtYAAAHwCAMAAAC109hCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-07-01 14:22:43 +0100" MODIFIED_BY="Cathy Bennett" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 H2RAs vs control, outcome: 1.2 Percentage of time during which pH is less than 4.0 inside the stomach.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAwEAAACwCAMAAABgv5JqAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAiB0lEQVR42u1dDXBcV3U+K+3qvtXK2rdayZYlW7ItI2bABGIptuWV
CSCTQLw0LTaUwiTNMO0w5S/uMJNC20mgpKWkf6FDw8+QlozJTFMg4KCEpMQMwVrFNpLCUBcaI8mW
4j9syfqJft7VStred9/Pvv/3dvV2tZbul1j79r3zzj333HvuPfftOe8GEDAwrGOUMRUwMAtgYGAW
wMCwLlEeLDWJkq0izjkR2F9sCs57IXNBUxBxD/Qu60/2Pz3nWQy/FXJ+uf+yg04IxbVD06+LIjXc
caWKJ//mSqEdn36s6YCL2JXf/p4odmMwXBUj/1ZB7FKcA7oJHC/bX7ulw4fym6fLr04N8IazD+1b
PY18B37PRWVXf35rQNTMPL56cY78K4mGvBP+003s4LEmUeyZxJWL4j/mBWV7IV8DQjwaSiYbY3EB
hPoY/6AAyWRdLflD/m+s5RsaYrF+EMIxvl680lgXC5Bem4SztXy0NrCCsuc7OS7TfR2gno/VE47J
QLxmC2VNywciy+aiKqP3U5DuJZ9yXUN1fCzeL8slk3CVUEfOxBJwZHMnHOEEUXaqMKJH5ZjSCw/G
+PhZhVdBxb4BXVRsqXy5XZLJLbWxpxSxOZgjZ/gDcGTTASp2tp3VY0ovylvXrPBa015QK4jT5hS/
99uJPWNTrXAJ3YZ/9K32rx/P/MVMKzz+pb8lBK1w+bd9my8N/eLv5r/VOT72DvHKZXTbXT9rhW54
6oaw/I6xeYlPPqhoOvmw+NnQNh5smyaspyvbhydE1rT8ze1f/+Humdfz55+zQj75k3n05VfhnFzX
muf/dekdF09Jcs3LKvvdf91OzvyKSCmIkj7ePl6x+wEi+7e+/LB6TOkfD9z47ZkvKnoraDt+7NQG
YQeck8tX2+XSb3/x9azYI4IkNhbF1rbz4+3//jQ9pvRE3snbifQSrzU+ByQJ4MXeQ3PoPPl2YQge
gAWoHgTR9N8clmjORwHGo7AMt8HQPGDxzCg8QS+N9z1YDUsrKD8BnDQXwNAw4Q/w4ggoiwJSPobq
IZgvpkKqO5r3V5NPua5jh+uraV01chGRv629RYChQVIRgF1c9pjSCzAY7R7P6q1wqBlsTsSysqjt
cj6qFTujvUXbzhg46fi83M5pIrZaF98QLEELoH7+robdkOKojpIZorjPKhrLfqYBOrtPdh4BqlBy
JkHv7H3odBUc6M6//FRC4JRSkidFWcSC1HKXyPdkURXywFvmyD8Aua6Nbzkz/BGxrhq5QDiiuyUD
5PsJRWHyMaWX7VvVW+Fwjfx3HdTy1XbhdGLr/FVtO9PjDMj0GUlstV5rfh0AwjxK4RA5CAkQgHL4
Xnf3hHUFyJVJ7ZlD8NqrKyo6ROZnWQjBQkEHxdOBYupipGcxNZKt6yyMmn/JfyNUaL8GdGrRHqfo
uGqhN9+RTlX0prPlW7ZLK2larVOuaedynYS9ktgB38UuWQt4KnGqMiHOUPEWeIS07kBzss7SaYcd
oWSt8m0n1RNuWVHREycFIUBK46BlByBDzxEPBlrUuag4qEiENHUtgzcOmAaMv4Yfa78jaJlKxpXx
NHssftspftPrrTAIHijXlW9uF+E6vKBvzWw769u8AlpChAnS1WUtrwOavvvypUuoq5lIOHuqAy6c
ODR12tL0L/S1Rc5MqYNdz1aI7Ny2tLKxK7pUH+2bhPO7Z9v6rihnIz2NSomHZvsvF1UjQclblesa
7p16v1Flm55/pU2nlt2zzadektdMmmPyrW9m2+lpg94Kg3+GkKZ8i3ZJ1ofv0YutaWd9m1/om42c
mdbVyx8ESjwyLgndwMBQOJS6BfAwyRqJYR1bAANDYcEi4xiYBTAwMAtgYGAWwMCw/qCJjBO+WcG9
e+LMY5oYexEOcfBn/+O918Ib0svulK6gQfCO0eRGhFBVmDv62hS583plfFrPS5NhoInr1wnoHr9u
gKIfGtZe87ptgXY5Csnzy8JXD14XIHTX2Lzxunxk0L29tsa68BRA8wGZE5XgnGUDqCeFbyCOx8uh
uyhtYzmpwsY5RUcV4eqFZX9THpKtN94lCfmW33gWkrTqu1/75WPCLyltAxUyNi3rleMCgWW/8zI0
c8CxPRsmu/e+PYcY+3d2fWdycu8nfBLlJVjMhTzWFZ2oPitGCXZfKX9bv+aKmECQTSJwiOt3jV/X
QdGPGNZedmvAtkBb/W2C1k5INJPPec2NOnjWfRgWyF+c/W1azKlwTKuAY3snq9priZLPiLRzsx+E
0JIUltZ0MHA1sqfa9+G1gobeXYOXvQsZ7Kr+XNdBaIHTIq0wQsaLRSlrIDRdfuVEF19IL+gBopxM
942oFAgv/jQLobqaRoB4shlCyRqR5sGYFDG/kf4wnYY3kTseVagBNh+Oh+BsbU0DjeGvVWPpZYJk
8qlYbchGkt73wyKNJn+Qj4VJxeMxPr5Fjvu3osek+NHucfGQex7eY0FBy6Zx/c11PF/TbyrRPX5d
C1k/tMAIWAUU0HyCqG2OwgL5r4fIvQAxNfYdhPjhRqq7gJLf4AnXpPAPOfJMGUmTIT5OOPJNMn+p
/VT5M4Pkjk3SD7WZ9BMQlx+FC4lJ7qKkSl8xTKM47zIKqeR+KHqP1zSoVxGM7iYKWpainJaiyxCU
o4H5To5r675eSAsog93xJoApyP4MG9xbeUM05TQcowEymwcqn20Xs0OuX6IuFNxaq+tXmVMdj8Ft
+7qlwXz8Ndjc/mykLVs/uD+yzy4aNXgvfFi8tn2gqrJrG1TfmJjtECfp5XDifksvCHY/0CQfv9lq
+pDKnhSrMzM2ObL/oJFg/mPAiaPx9vZIpH0b3D4+ObdPjOZdGkr8maWqqH4oXoWPmAka2iPh9nqq
P5WXFktESkz+LsH1be3PVg1spyNzxylqVMBVJu6fBK8/gadPJfohkDiVNpwOdzTu6OBGZf5S+ymN
IxpNhnSuuaN1IbgvBAIelq58GF4viIvNncZN0I9PG4Qc4fb37uioTMt6f1dHdzZGNSAKeS9R1Af4
WgHKQmWh8JB0ZbFA+RgaC5juhY5b6s5qryIY/AXAVWKUn6RGKcBQNZ3Z5uns+1Iv7HtIe8eFIXiG
TMzVUnTfvDmW/sIg2P0EF/p102CIljE4RAoc31q/gUbvqnH/Bkwh+PUtddKMYogyVyYJtWzC7KNm
Ei/x62CtH85KJjWfwDpHIdVxdrFnIpUWOlJpNQ6e6GtIst6JEet62uDf4BAZzv9FM7TS2eM8mmvr
fVGJs5faT/VJjodJxTK9Mx17PwNtkfB2bgdPR6fBQgX6VZDhvxNCRiHl3A9Z73th94XsOAg7w6Ie
Un8S2bcVwhGuDu3gj4lXEgUSUmMB6csDvbD3du3VTuB2kXEjtTi12DtChxHyfQmUMP1dl/9SfwfH
wUmi5F1puZuIsfQ6uQmBXVzxC0Qj12gZR46Q+xpuWdpAypfi/i1HwSdfScHeqDSNW3HVlN14y/Iv
KDODJ6HGrx+h8etfq4IDUomdVgVq9GOTp0frTx0shZd2koN3dQa5YGcTOVqCz8rx/CeBU7WVS+bH
3akPCbjno6B1sUUuvYkM2qXwl9pPxsSZj9XuLIPrN9J3w9fgnsnhhTHRzwZN2KvfGDrJCeGTw0Yh
d3GJTpr7QfWeEdWm4LXTszXEM70+sWuIjPqXJ4eF8x+c/XQhhdQ+DeUuX35FHrhSQC23RwyFJ4ed
b+ikftl94neNN8HtvzxAenyP0iUEKZZfUK2+XDp1UiE4a1+LXb0LqTTIEeBTMOca5c9dujIgez+t
Vpk+mjj+GRi1mEK9xK+DtX42WKcWqfkEVrwqyMiMiFoXyb9sHHxAUnHuHkZwsCkRTJtmUiHVO6/y
79EyT1+bvP5EebbZj8+l90eXJYdyQ2EsgEOJ2H5kGrvF3A/aR6jee7VCctcnxpc1um2p4AbTGWkA
aS20BdQkt3DPiNMQHVKnaqkjsXMb+XgO9gBt0KegZQB6NXcEuB+RO+6Dpm30xPYWos15GAhmW53G
0pdDs0RwcKetFwRf7nxEGgtbppK1hOcbnaP848l+LijNsESDYTOBHMcvjh3lFhH14CV+Xec0yfoR
C4zBmEV7S/kEdjkK5WRIvga/gf3wI03s+6PQsi1Ls9P7QDdGGoWTn0BotJKIdHc+pvCX20+iicem
tiTGIc7/TwtthI8vQqqZtv9ve3ihryDJAhXQJbrPBiGPJU5VdgYVvZP+sl0VsvZoaAsZbYmsYepo
4FchFbpPvFLZI2VtFNACXj89y3/+zM9ojP1E6qNi31o8NfMVsWl7oJe6G+f7Zg9lI+bh52eS0YNn
JqEjNSMlKJXP9f4UJl7+p5g4LVC/v+/QbN9lmOh9/TmpuJnTto8cHoLPy2VsO/0zwvOWG46ST5/p
ik2fECNHk5sXfzlqJpDj+MW4/srU1PMWLFzj13VQ9COGtR94xWLhIecTiPqbTJl5jRItpiHaCz1v
1sS+t52aL1O0JeU3eMR8AFKDdJ7WoLn91MX9bzjeJPOX20+iiQS2zRGxq0IH5vqI491flobwFB2f
oyeWN33hRCFeVTLYAz0mIZuOS7kfst4XX/5SmSrkC69F5gYuwXT5tmjfeUIKUQhX0hSCkROLm6Mn
/I8U9hIbKkDD/l+NembJVw4Pfva01WMrFuxv8bNGeHjDnafzf8jXNDvuC01B0fz6DV9oCgEvFhDL
lFXmMED037EEocoRK9tgwf7mBohlMtba8oa6sYwvNAVFnYcK1kZGStYCGBgYGBgKicOrVnKQzQEM
pYBV64csOpphfYNZAAOzAAYGZgEMDOsT+vAW7LIika/rP8iBn8sYLLNWmZtkyp4xCuLE0kxluls6
wqaFGTYKk2eBhotGnshWk0Z+RkGxegF5UpD2TlB4oSybwkMMaAqVngVg5Nyb5ev6D/D3HdxYfTKA
bWTKnjEK4sjSRGW6Wz6yqBKyuyWnArUXrXhiZGcA1vXWCIocCU2SIKOiJQqEYf0haBxpaCvIYwzC
yugk6a8IIwRWW8FxYkF5sfTMw2xy4EOB2ou58JRvQR4ExbZVRLZ34mI/iBRD4H4gf3aXlAWoqsJI
PzQ5j/LYz6HDU7vkNlujPMwQcnIOcykQOfC0qTPyKijyrrFVNAC115dGkFjQU1Nm+3jR9YUs1gHI
qo/m5XEhl6J0g0J2TYBXPh9a8CT/O9u2R8vXiifP4sil4fyo0ZpYCee9ci2kW+Q61EmdJ69eaLUw
cBiD5ZLc1gE5zROK9JY9FRs8GdtSsWH6VAilW5DbfOZDjXJDqIQtwFERVhdxIZSHC+vn5Ft2IToJ
cnAnkVdBUW6lraYTVGIoM0yF1hpxWp0ihFZ5AsUFvg2vtCR/eOKiaWb9ekGKN6j3CrNOBpbmUPly
EXxHjCxKQcqTqtwEMVHp77Ysyt8CHXkqxwhyuMUjYfaE3RyyjtcBHvMDMAshLWV4ax53qtVr5uSq
PRjysBLGsG7HhzVmAsxpys8CWO8veSB/qNZlS7PIOIb1DWYBDMwCGBiYBTAwrE+UWn6ATeS6kQqB
gQTcf8m2DDACL+kGplh+tyo75QfYZCU45gcYWwcbVJNrfoANBS7uWpi+9DRUUhZQAvkBNpHrFmai
JUbuVmWVaGA4bx/9j4wKwnkVaFmIh/wAc+sgw4kc8wNsKNZlfkCZceSSQiMw/QtYimXHmk5ZeOhj
VpA7MfYcPWN3XteNvAYt51ygbzp0qZF7tFAJPPaUuhj9XF27K7X8AC9BW9gYrO0SJOB23nXyNzsR
jlVGfvdsd4FKpmPnMtmnS0Lmks8P8BIVv7LQXk1IMrb28o2x/IUYwt3zAzSxO0ibbeyoMjuGyvni
xXjdHCvhgg5c+Y8WLkmLaMWjkV1RRgJNfkAhBkXbTBasiKbLVtXmRdglEpgYKsGPuaVaFwShErWA
Vc4P8BC5ni2wQI1mzxb5UGX7etn6VsiD7eZu7wzGlXBJ5gdg9wKxz0XZp2BiH6rsg9Vi53q75x6w
vAGbOaB08gM8RK7nGtzuOfofGxeangPzvRSo1+GK8gNyzWcwaQwjtg5g+QFrAiw/oKArYZYfsFZM
IHePkz0LYmunmwIsP8CflTADA7MABgZmAQwMbB3AwFBopKWPUClZwAryA3x6kGaxcYD5NTf6cGXw
WLhDfoBrRgLWR9PnW6Beh973D3BTjSE/QBfFZLPfAV79/IASnANKKj9ADVC1kQLA9cdRcK6c8U3+
9hkJ2MAjzwJ1Z3PYP8BdNbr8AMDWDeZQI5YfkB0W8s8P8CvO2+3l/ch4Lc/px+puDxkJsLL5Dq2E
hYtqTDWyy3iwUmbRgSGH8auY64B88wNc39CdVyuDh2wTtKK+aOFU2dTQ126D80jFcVONd33gEhju
UXrVjdB1JZxTfgAq3ChhPp9HYZ52B/BhkHctEMvhybnvH+BaFVtVYfdtONZrtFzp5gc47AqQ12zj
vjuAzzW0LxAjr/sHWE8Y1n49clAV0q98sW9bMKxFCyiZ/IBVyEazcdJxQWPGkLtr4r7eyXX/AGNl
12/oi3/5AX4PITjnC36VY6ylrxkQpsdXhRx67Z6VaWrkmG1ZWIQklNIcsKL8AOTn02SnWHy7t+Hn
6Tyb2GH7nYZ8yA+w37XALT8gVzE87R+gb9L1CJYfsBbA8gMKuhJm+QFrxQTydjzX10o4/0UWw2qB
5Qf4sxJmYGAWwMDALICBga0DGBgKh9LIDLCygFXNDzC/BVeNAHZ++b2HF6hbVs7mTf4O7Az7FuRa
oFOpjvkBFtsCOOwfoBPPWofWrFh+wKrmB5hfuq82HAZrKeUjbzLYvUQ/B3amfQtyK9CxVKf8ALNq
HPcP0IpnrUMbViw/YDXzA7D9W+9tg4KRHYknIE/C5E3htVTPkXnutXV456rnLQeKgRLJDLBbCUuj
gRwjJL0pGWEPDbTCIQSZDAl7Tybx+bdMR1+kEAU6c7V49aL1aGM2AHcdrsYGFsiz8a/2Sng18gO8
JNpgQLl3RWSfLFuYMDXHN54i43rHS34ANu0fsPJxOOvKsv0D/B24Vj4XOLxD1tf8ADXwzyVIPp/N
lBzelG68aJkfYL0tAPK86kbWhJo6r0ina9MCVjk/wMTXgzz5Fm/sTy4ug0/7Ftj66Bb5AfltC6CN
czXqcDX8fhNCJWQBpZsfYBuVj/2af4yh8ThPgXwyAK9+Sw6qthPZxGodbyhQavkBHoL/syQYcghr
N7nl9m/y98fr87h/gFoJ3/YPcDc1tn9AFiw/YC2A5QcUdCXM8gPWigl497PYs6C8VmMMqwWWH+DP
SpiBgVkAAwOzAAYGZgEMDMwCGBiYBTAwMAtgYGAWwMDALICBgVkAAwOzAAYGZgEMDMwCGBiYBTAw
MAtgYGAWwMCQK/qbSkGKcvbqXIZVwvdhRj1uPcfmAIZ1htDCh0rMC0pSKN+aajUX6MeWGght5GNh
Ac5KlJtjDQDhgEwf5/kHQyJtTWNJKbq5jo/VNgM01vCH+4tSYG2MryUTfGMsFjfM83VEk6EwH9tI
dLjxfaK+CISNMT4cggZ+M8DGLRYMa8W7HuT5jWflrlOTVM9L7abl30TqW0cpQ2qD1iV1XW8jz0sU
sm5kWTSMioHg2LdCpWUB3d3SPwm37DNQCkcQxPecqOyKwXvg7m5CiasF0p4Zqdmny69ODfDiYcW8
UEoWMJ+untk3DVtuDc+eeE8xCpxb2jC7bwYCt0aql2d1Pa92L/kb74pU7mmC2/Z8LjIQF08f2xOu
6oqDMELMYvGieaiMiy0RH6h6bs9tskXsz56XWk7Lf3YhumHvO8Tvi3BCbCb5fBbRPdVTe2+XdBOt
3vcHoixVRJbivq5BCML4ptJcCT8Yi9UD6ctJouQYH1dGpR2D5SBA2xDcBUvwefHM8sgSxDm5n3Vy
XKb7unj47P6WUrKAa5OjpyAI+OSl9OT1YhR4fWJ0EwQgnro4MjGuvXAn/bsAQ0NwAMKwe4gcEzwP
w4PkaCmagYNhM7s7A9Jdg7tBunp2QXPezH98auQcaSGCeohpzmexCKMZieLa5MgoPCnKMlj0F0Vs
J0PnfElawOaBymfbN0+KI0v1jYnZjjn5fBoGSbuS4f0E/A3MxWoFKJsqExaGlavqUuZNpfbWjZqH
Xh6Fj5TVijIXBUff1nsJlv647midbpo/85r4NwMcR3R4r/hB58+t0lFZc1loYcjM7MyUete99MRt
NzTnzfwJBiAg9fR5XpRAPS8DQ38//IN0fPgQ0Q2VpdgQxtW9ZErMAjAMVct9eHxr/SdhWbUADkKw
8zg5/KvUTOU+0nDbwjsqvss3iFcToOowII0vpYPLr3Q0w2BiPLKvSI/f/n5g/1ZIDKKOvbxuNgpL
mqIYlPp19ig8xdWhHfwx0xyWVu96gvqblRnNeTN/0gCHoFI6mKna+5nseQUT6KGHejqk4yfvEXWj
ylJEZEqkd5RZSMbtkvtwwy1ffBo61Y4NMHr37Cd6iUon0kNkhLk8MTx/4dOzHxSvpkAdX7mSqZwi
0BC16PnBYo053DDRDunad0tujh4p6aNH0alydHlyWDj/wdlPW7NMqZ1m/oZL6VN84hW6nLj+o/Qg
fN1M0IR/9WznO2VRRRmzshQRESiNFxRZPQ0VBDgorengnlc1liEA96cTY8uhrA0PIC6RpiNTCFrV
24uuTHeUa7pQkdBjo96AqN8uIpEgjxldIISoyloquMG0VkTNw5kyEM5K3PYcSoprND00lKHt8IVL
2uJMhAviOiCt6QJUlmI32tBbS+Md0uYm4qBlAHpJAwpwH7RmF7UV4lMIPtTYiSAeawrTZdn7EOyU
ahHeKQiBZJ14uKG0NqiM881nxVfVwo7/Lc4CpSY2tZNoMQwtO8Fi4UFUNgDPkcanl0mHTMHARqpd
/CqkQveB9umc+niGkN8JXxbJ6UnjYxsNZTwz00a7OtQebdqZHWYlGxEJg+I6oFw8IeuGylJR7Jl5
BJLDJWkB5/tmD/VdgW/0bIGO1FuzUy5ZA8AL5ZX7yAz7Uvl0dPd5Mp2WjUBbhHqZI08v1Uf7JqUF
2FdLyQKqQlPvJvW52tfWtXuxGAVuKN82Qwq80jc7e2bCfHnsxMwhcv7FM7MzkjwXzhyaPUGWhU0Q
hXCkzZrp+G7CrcNL8ThxpzwjVD45feuJC/pJibpJu7q6Tr+k0Q2VZbzYDbMI/VwJ9I+AZ1dM2Mxd
8URYv3CZA4aiIentQX7z6zd84uQXaoNXs0V3l74FQP8d3oaJWu4i65ZFRCwDk16aJTLiQsGDJ0b+
9b2mkZvLAhgYCjeRrZoFsMg4hvUNZgEMzAIYGJgFMDCsT7CVMIM18tya7Ka4TXsfmwMY1jeCJsPQ
bEiOcrcs4z3ZvXIlAouNKbOn5F1uwUBDd0U33KXZ/1beit0krI4kywhp+NpLo8jttrkxw1qygBUD
Wc42mg6E1B5udZtMbLVBvcmwkK5bIxeSbOcGpKWzlUa+mf7PDGAdWgAdAbG047k0CqqH4rCI1UES
y7ugZ79hlV7pldIxVrdQR+6unHaglrqpgSqnTilPEvKHjr8nadbrQmAN3+ZmAdIIiGSnJjseKsOi
ZoRVBspsb8emLoo0DhJWnBow+D52BiBZHs5ODI5d1pIE6T/kaQY8SrNubWJNr4RtLAB70wbCTmpC
ln4DsuyNqiuCHCRQizP0dWSxlEB5NbKdNGLRyrTGsB68IKT0JuxuFNivyQiBvr95vk23vijQwIes
1/cMa30d4KFv5eCXW/QfS29F+W7X37CHovIyCKe7MMKsl6zLZ0EOD0WxtQuOsm4QaA+tOjTyVJBh
fkHu/l9+Y7UHxmwZsJZu095naQFIfYqPsGYFSQ9lVwVhg/9iGMDlD4RdpUTKcyQDscTBxjPKkto+
rMzytVrmu0ij8pfEWsdmgZHm+QD2MAUjdzLLG3PWsffCHOuQV1SEy0DpzzjqlUuupWH2G1dO3QyB
8XGga1fLWcN5tYnnwpzrkHNUBCYohgF4n9BwQQyLIXdtFVW3ngtzIcz5N2HkA4W/Lh7KnS2zgsL4
2biYqvVaGAJ/LYCBwamzFW8e8KkwZgEMfoznWA76KtnpiVkAQ0F72M3rV7L8AAY/p42br7AAMrK0
jjzL7Zm4KZAAm56qG0KBkN0UbH6K654PoL/HwIE9Dc2to+X4e4AXMn+W0N4Ly+H3AIzs7ka5qg0j
J4sA03XTRWwI1Nf81oZRDvcYOGDLZAKGdQsrLwhjrH5gOVIOK6exPGjLV8FwRb5Xz4tc0V5U+GIH
w8vFx8Q5D2kMDA4rYd2gidQkF01GgMGXMCcRGHghXRYB/V8bpe/kDpn8L4xWNH9qkgQYGFyfBSGX
c/pcAOS5M1rmoCDLgV0yGUN8kSa1mPVkhgJ5Qcjo0Di4FllKSy/I7qKtY4KykRdKR0e6vBwClZJF
L9+EEEqGc9DBU/A8wuoDOrHtaO8WwJSl8T6ysyc7fkLaZcMvZg6MGqypfCi/0bMMjl6Q17wohE1Z
LdhxjDc/WjKM9nn4NswA/EN3kXjt7y5U+R05siiz6tXUB5E/1B6NdEGh2m+aY2QIHNXdlGUs8ZUe
DNFoU2wpAjYJ4xAKanePiQNbPriiv5avaYCaEJyNizvQi1uyJqUROtkQgy189HA/pZOu1TZB00ZI
PkXpBGnTWpFOJG+MHX0qUBPtB5XP5sN8P7mUhOY4H9uysvKbD8cChHNdVOIsliNyJmWAEPe4eW6Z
xWgqO9nSB1KDKeXvWVdcvUNzBSF5QYy0ZEjLARS+yr1Zr17r6IPhHuQ26NvdY+DA+r477nhhMjwP
FS/BnRUQDE0e13gKz1yB2eemnv47+iU+MfnjOERmhdkJgE9dPR4HeGpqYjwm0YlYunLPxzdfnu4i
3galBcg8eeIYGeq74Q8jk5HZlZU///LM/USK41MVlLNYjsgZyp+EY9wE15TnHFDi8CNvl00Btr47
3YJsvA0uJeB3z0C6W9yLtlqzK9YuDoJdgfnvS3pMQzuGkbmtFWmAn3LVpGn+PA2ZgxKdiHGurWOY
y3QCcJQW4ALXRvcvhkdG4WJiZeUvDKcfJdPObhgSKOeMvPXvIAfPDMHgXi81Lr/5QuOCJcFibaK1
+9w58nH2B5Xc1nPCH00+8hU4eC88xgnQSs6Tf633Atz4asU/bqI72h9sbW0dFaBh/uLD0HqU0nWR
Uz0CpRPJ/w+UQ5lWuXAOQvVceCs9yr/8e+W/D4e1nOkROXlN0HNfI3MAQ+Hx9kDFNBm1Q9vJXEm6
s6B/zsiNXa2apkc93d3dk2QoLt8hdlsQiFOekk6Z0WO8EM2MVa20fHoqJVg8AhVPetoimVkAgxmZ
0KA4Tf6wjfzFYRgg3svOgLBNvhrfwslbduMQ9NVCKH1JICvRgzBAOuyjIdgSt+LJUVq1g4ZgcWwe
r7D8ipYQWXMIZ6EFabs+9bHCsPMRZgEM+SHSXv9N8lHdQzz2xdro3YsA90Q/oPSV/97LRyP0aJHn
vxQBPsL9hCddif/9cYA2np97yYrnOB/9UiTrh1bB1IYPlK2w/In5qhcJxXv5hew2p8F66aFonBc8
7b/MdtBg8GkN3X1zyl3OFoUMvuB3N2l0CpsDGNY32DqAgVkAAwOzAAYGZgEMDMwCGBiYBTAwMAtg
YGAWwMCw9vH/OtJKn22ZNdkAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-07-22 13:51:04 +0100" MODIFIED_BY="Cathy Bennett" NO="3" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 H2RAs vs control, outcome: 1.3 Median intragastric pH.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvkAAADQCAMAAACqXo6dAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-02-09 12:07:02 +0000" MODIFIED_BY="Cathy Bennett">
<APPENDIX ID="APP-01" MODIFIED="2009-02-09 12:07:02 +0000" MODIFIED_BY="Cathy Bennett" NO="1">
<TITLE MODIFIED="2009-02-09 12:06:57 +0000" MODIFIED_BY="Cathy Bennett">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-09 12:07:02 +0000" MODIFIED_BY="Cathy Bennett">
<P>1. randomized controlled trial.pt.<BR/>2. controlled clinical trial.pt.<BR/>3. randomized.ab.<BR/>4. placebo.ab.<BR/>5. drug therapy.fs.<BR/>6. randomly.ab.<BR/>7. trial.ab.<BR/>8. groups.ab.<BR/>9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8<BR/>10. humans.sh.<BR/>11. 9 and 10<BR/>12. (night$ adj15 acid$).tw.<BR/>13. (nocturnal adj15 acid$).tw.<BR/>14. (evening adj15 acid$).tw.<BR/>15. (bedtime adj15 acid$).tw.<BR/>16. (supine adj15 acid$).tw.<BR/>17. nab.tw.<BR/>18. (acid$ adj15 breakthrough).tw.<BR/>19. (nocturnal adj15 intragastric).tw.<BR/>20. (evening adj5 dose$).tw.<BR/>21. (bedtime adj5 dose$).tw.<BR/>22. or/12-21<BR/>23. exp histamine H2 antagonists/<BR/>24. exp cimetidine/<BR/>25. cimetidine.tw.<BR/>26. exp ranitidine/<BR/>27. ranitidine.tw.<BR/>28. exp famotidine/<BR/>29. famotidine.tw.<BR/>30. exp nizatidine/<BR/>31. nizatidine.tw.<BR/>32. (histamine adj3 H2 adj3 antagonist$).tw.<BR/>33. (H2 adj5 receptor adj5 antagonist$).tw.<BR/>34. H2RA$.tw.<BR/>35. or/23-34<BR/>36. exp anti-ulcer agents/<BR/>37. exp proton pump inhibitors/<BR/>38. (proton adj5 pump adj5 inhibitor$).tw.<BR/>39. exp omeprazole/<BR/>40. omeprazole.tw.<BR/>41. (lansoprazole or lanzoprazole).tw.<BR/>42. pantoprazole.tw.<BR/>43. rabeprazole.tw.<BR/>44. esomeprazole.tw.<BR/>45. or/36-44<BR/>46. 22 and 35 and 45<BR/>47. 11 and 46</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>